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Summary 
 
 
Background: Atopic eczema (AE) or infantile eczema is a common 
inflammatory skin disease, which affects 10-20% of children in industrialised countries.  
Australia was the 12th highest rank of AE incidence in 55 participating countries.  AE is 
characterised by poorly demarcated redness of the skin and associated surface changes 
such as scaling, swelling (edema), accentuation of the hair follicles and skin thickening 
(lichenification) as a result of chronic scratching.  There are three common quoted
 
diagnostic criteria for determination of AE for the purpose of research and clinical 
studies, the Hanifin’s criteria, the U.K. Working Party’s diagnostic criteria and 
American Academy of Dermatology clinical criteria for AE.  In addition, reliable 
scoring instrument such as Scoring Atopic Dermatitis (SCORAD) is fundamental for 
clinicians to verify the severity, the course and outcomes of treatment for AE.  Certain 
quality of life (QoL) questionnaires have also been developed and validated for 
assessment of the personal impact and outcomes of the treatment for AE. 
The conventional (western) medicine treatment for AE is not 
satisfactory.  Complementary and alternative medicine including Chinese herbal 
medicine (CHM) has been increasingly used for AE.  There are some promising 
published evidences on oral administration of CHM for AE.  However, the benefit of 
topical application of CHM for AE is not clear.  
Aims: a) To review fundamental knowledge of AE in perspectives of both 
conventional medicine and Chinese medicine (CM), b) To evaluate the effectiveness 
and safety of topical application of CHM in the management of AE by systematically 
reviewing current available randomised controlled trials (RCTs), and c) To develop a 
protocol for pilot randomised double-blind placebo-controlled clinical trial for 
evaluation of the efficacy and safety of topical application of CHM for AE. 
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Methods: We searched any RCTs with topical application of CHM in electronic 
databases and journals. Trial-design quality was evaluated and intervention outcome 
data were extracted and analysed.  Meta-analysis was conducted by employing RevMan 
5.  Development of a protocol for pilot RCT of topical application of CHM for AE was 
under the guidelines of Australian Clinical Trial Handbook issued by the Australian 
Government, Department of Health and Ageing, Therapeutic Goods Administration in 
compliance with high ethical standard. 
Results: Three studies involving a total of 452 participants were selected for 
analysis after screening 164 potential studies. All three included studies reported 
significant differences between the treatment group and controlled group and claimed 
that effects of treatment interventions were superior to control.  However, due to the low 
quality of study design which resulted in low level of evidence strength, these claims 
require more vigorous scientific proof employing well designed randomised controlled 
clinical trials.  As a result, a protocol for pilot randomised double-blind placebo-
controlled clinical trial for evaluation of the efficacy and safety of topical application of 
CHM for AE was developed. 
Conclusion:  The systematic review in this thesis is the first one conducted in 
topical application of CHM for AE.  Detailed analysis of the three included studies led 
to the conclusion of low level of evidence strength.   Thus, they did not provide 
convincing evidential support for effectiveness of CHM used topically for AE or 
infantile eczema.  Therefore, there is a need to evaluate the efficacy and safety of 
topical application of a CHM for AE through a well designed, double-blind controlled-
placebo clinical trial.   
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Chapter 1  Introduction 
 
 
This chapter describes the general background of atopic eczema.  It also outlines 
the aims of the study and organisation of this thesis. 
 
1.1 Background 
 
Atopic eczema (AE) or infantile eczema is a common skin condition which is 
characterised by poorly demarcated redness of the skin and associated surface changes 
such as scaling, swelling (edema), accentuation of the hair follicles, and skin thickening 
(lichenification) as a result of chronic scratching.  The stigma of a visible skin disease 
can affect a person's self-esteem and severe disease is associated with a poor quality of 
life (QoL) (Schmid-Ott, Burchard, Niederauer, Lamprecht, & Kunsebeck, 2003). 
Current treatment for AE has limitations.  Topical administration of 
corticosteroids, as one of the standard first-line therapies for the management of 
inflammatory episodes of AE, can be associated with certain adverse events such as skin 
thinning.  Long-term application of steroids has been a great concern to those using 
them and to healthcare professionals (J.M. Hanifin, Cooper, & Ho, 2004).  A study 
showed up to 72.5% of patients or their guardians were concerned about the application 
of corticosteroids which could lead to potential side-effects for their treatment of AE 
(C.R. Charman, Morris, & Williams, 2000).  New drugs for the treatment of AE such as 
tacrolimus and pimecrolimus [these two drugs are categorised as topical 
immunomodulators (TIMs) or calcineurin inhibitors] (Eichenfield, et al., 2002) have 
been developed as second-line therapies.  However, issues regarding the long-term 
safety of these new drugs, particularly the potential link between TIMs and cancer have 
been raised (Centre for Drug Evaluation and Research, 2005).  Therefore, many AE 
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sufferers have chosen to use complementary and alternative medicine including Chinese 
herbal medicine (CHM) for the management of AE (K. L. Hon, Ma, Wong, Leung, & 
Fok, 2005). 
In Chinese medicine (CM), those with AE are recognised as having a specific 
constitution that leads to internal dampness-heat accumulated due to the reduced 
function of the Spleen.  Symptoms can be triggered by exposure to wind, dampness, and 
heat pathogens (B. N. Zhao & Zhang, 1983).  Clinically, AE is classified into the 
following patterns from a CM viewpoint: Accumulation of internal dampness, Excess of 
dampness with Spleen deficiency, or Yin deficiency with dryness of blood (G. T. Chen 
& Yang, 1991).  CHM is one of the important components in CM for prevention and 
treatment of diseases.  Botanical resources such as barks, seeds, flowers, roots or 
mineral substances are prescribed and administered in forms of decoctions, pills, 
washing lotions, or ointments for conditions diagnosed by a CM practitioner.  CHM has 
been employed for the treatment of AE for many years.  Chinese herbs for AE may be 
administered orally and/or topically (D. C. Chen & Xuan, 2001).  The formulation of 
CHM for oral applications is guided by CM pattern differentiation method (Bian Zheng 
辨证) known as "individualised treatment" while topical administrations have been 
devised with little or no consideration of pattern differentiation (Guo & Yu, 2007; Zhou 
& Li, 2008).  Efficacy of oral administration of CHM for AE has been assessed through 
clinical trials (K. Hon, et al., 2007; Zhang, et al., 2004).  However, topical application 
of CHM for AE has not been properly evaluated in terms of efficacy and safety.  Given 
the wide use of CHM in AE sufferers, it is important to systematically evaluate the 
therapeutic effects and safety of CHM used topically for management of AE.  
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1.2 Aims of this Study 
 
The aims of this study are to (1) review fundamental knowledge of AE from 
both perspectives of conventional (western) medicine and Chinese medicine, (2) 
investigate the effectiveness and safety of topical application of CHM for AE by 
systematically reviewing the currently available randomised controlled trials (RCTs), 
and (3) develop a protocol for conducting a pilot randomised, double-blind, placebo-
controlled clinical trial for the management of AE with topical application of CHM. 
 
1.3 Organisation of the Thesis 
 
The thesis consists of six chapters.  The current Chapter One provides a general 
introduction to the background, aims of the study and organisation of the thesis.  
Chapter Two reviews the definition, aetiology, pathogenesis, diagnosis and treatment of 
AE from conventional (western) medicine and Chinese medicine perspectives.  Chapter 
Three describes the detailed methods used for the systematic review and outlines the 
methodology for development of a protocol for RCT.  Chapter Four reports the findings 
of the systematic review, including details of the study selection process, characteristics 
of included studies, and effects of CHM by comparing them with no treatment, placebo 
or conventional medications. The significance and limitations of this study are 
discussed in this chapter as well.  Chapter Five describes the development of a protocol 
for pilot RCT in management of AE with CHM in topical administration.  Chapter Six 
is the final chapter in which the general discussion and conclusion are presented. 
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Chapter 2  Literature Review 
 
 
 This chapter reviews fundamental knowledge of AE from the perspectives of 
conventional/western medicine and Chinese medicine.  
Section I: Conventional / Western Medicine Perspective 
 
 
2.1 Definition of AE 
 
The term eczema applies to inflammatory skin disorders caused by either 
exogenous or endogenous factors or both.  The exogenous group of eczema includes 
primary irritant eczema, contact allergic eczema, and infective eczema secondary to 
pathogens. Endogenous group includes atopic eczema, seborrhoeic eczema, discoid 
eczema, pompholyx eczema (hand and foot eczema), static eczema (venous eczema), 
asteatotic eczema, xanthoerythrodermia perstans (superficial scaly dermatosis), linchen 
striatus, photo-provoked eczema, and neurodermatitis (Graham-Brom & Bourke, 2007).  
Among the endogenous group of eczema, atopic eczema is a common inflammatory 
superficial skin disease characterised by severe pruritus and associated with a personal 
or family history of related atopic disorders such as asthma or allergic rhinitis (Beers & 
Berkow, 1999).  As eczema and dermatitis are synonymous (Graham-Brown & Burns, 
2002), the abbreviation of AE or AD is interchangeable for  atopic eczema and atopic 
dermatitis in this study.  In addition, as there is a consensus that infants or children 
under 16 years old who were diagnosed with “eczema” are also considered as AE in this 
age group (Simpson & Hanifin, 2006) and AE usually starts during the infancy 
(Carbone, Siu, & Patel, 2010); therefore, infantile eczema or childhood eczema is 
regarded as equivalent to AE in this thesis. 
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2.2  Epidemiology of AE 
 
Industrialised countries have reported a higher incidence of AE with around 10-
20% of children being involved (Kerdel & Jimenez-Acosta, 2003).  AE affects 
population from less than 2% in Iran to over 16% in Japan and Sweden in the six to 
seven year old children and less than 1% in Albania to over 17% in Nigeria for the 13 to 
14 year age range (H. Williams, et al., 1999).  Data from the International Study of 
Asthma and Allergies in Childhood (ISAAC) on symptoms of eczema were published 
in 2009 (Odhiambo, Williams, Clayton, Robertson, & Asher, 2009).  In this study the 
authors found in six to seven year-old children from 143 centres in 60 countries, disease 
prevalence ranged from 0.9% in India to 22.5% in Ecuador.  Amongst 13 to 14 year-
olds from 230 centres in 96 countries, disease prevalence ranges were found from 0.2% 
in China to 24.6% in Colombia.  Although industrialised countries have previously been 
reported to have a higher disease prevalence (Kerdel & Jimenez-Acosta, 2003; 
Mohrenschlager, Darsow, Schnopp, & Ring, 2006) data from the ISAAC study suggest 
that eczema is a big problem in developing countries as well, especially in Latin 
America and some countries in Africa.  Australia was the 12th highest rank of AE 
incidence in 55 participating countries (Kemp, 1999).  The prevalence of AE has 
increased over the last 10 years in both developed and developing countries, especially 
in those aged six to seven years (H. Williams, Stewart, Von Mutius, Cookson, & 
Anderson, 2008) for reasons that are unclear.  Most children with eczema improve with 
time, but around 40% persist into adulthood (H. C. Williams & Wüthrich, 2000). 
 
2.3 Impact of AE 
AE is an itchy skin condition which can result in sleep loss for the child and 
family members. The cost of care for patients with AE ranged from US$364 millions to 
US$3.8 billion per year (Ellis, et al., 2002; Mancini, Kaulback, & Chamlin, 2008) and 
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employee disability due to AE and increased sick days occupied for 38% of the cost 
burden in the United States (Fowler, et al., 2007; Suh, et al., 2007).  It was estimated 
that the total annual expenditure on AE in the United Kingdom was £465 millions 
(Herd, Tidman, Prescott, & Hunter, 1996).  An Australian family and community had to 
pay AUD$1,142 per child with mild AE a year or AUD$6,099 per child with severe AE 
(Kemp, 1999).  The author further pointed out that AE should not be considered as a 
minor skin disease but as a condition with significant personal, social and financial 
burden both to the family and the community (Kemp, 2003). 
A recent published prospective cohort study over 40 years showed that 
childhood eczema was strongly associated with the incidence and persistence of adult 
atopic asthma.  The implications of this study are that prevention and rigorous treatment 
of childhood eczema may prevent the persistence and development of asthma (Martin, 
et al., 2011). 
 
2.4 Pathogenesis of AE 
The causes of AE are still not fully understood, but probably involve an 
interaction between genetic factors that determine the integrity of the skin barrier and 
immune responses, and environmental factors such as humidity, irritation from soaps, 
microbes such as staphylococcus aureus and allergens such as house dust mite.  Most 
children with AE improve spontaneously by puberty, but around 40% persist with AE 
into adult life.  As mentioned on Section 2.1, most AE patients have family history of 
atopic phenomena, such as asthma, allergic rhinitis and AE itself; therefore, genetics are 
fundamentally important in term of AE pathogenesis.  Genome screens of families with 
AE have shown chromosomal regions that overlap with other skin diseases, and 
inflammatory and autoimmune diseases.  The findings suggest a hypothesis of immune 
dysfunction in AE resulting in Immunoglobulin E (IgE) sensitisation and a secondary 
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skin barrier disturbance (Morar, Willis-Owen, Moffatt, & Cookson, 2006).  In addition 
to the genetic susceptibility, the interactions between genetic susceptibility and the 
environment where the patient lives have been observed.  As indicated above, incidence 
of AE in industrialised countries is higher than that in developing countries where both 
groups of AE patient exhibit equal genetic susceptibility but elements of the 
environment in industrialised countries have triggered the development of AE.  The 
roles of epidermal Langerhan’s cells binding IgE, T-lymphocyte activation, T-cell 
proliferation, epidermal lipids, cyclic nucleotide metabolism in the leukocytes, and 
staphylococcus aureus infection in AE all have been focused on for explanation of 
pathogeneses of AE (Graham-Brom & Bourke, 2007).  Figure 1 outlines pathogenesis 
of AE. 
Figure 1: Pathogenesis of AE 
 
 
 
 
 
 
Epidermal Langerhan’s cells binding IgE, T-lymphocyte 
activation, T-cell proliferation, epidermal lipids, cyclic 
nucleotide metabolism in the leukocytes, and 
staphylococcus aureus infection 
AE 
 
Genetic Susceptibility  
(Integrity of the skin barrier and 
immune responses 
Environmental Factors  
(Humidity, irritation from soap, 
microbes and allergens) 
IgE sensitisation and a secondary skin 
disturbance 
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2.5 Clinical Features of AE 
A most typical form of AE presents with red and inflamed skin on the face and 
associated with intense itchiness (Figure 2).  As time goes by, the neck, trunk and 
extensor surfaces of the limbs are affected and finally the flexural surfaces of the 
extremities such as antecubital and popliteal fossae become involved.  Although 
patients with this condition very often have a dry skin (xerosis), impetiginisation may 
occur as a result of secondary infection of staphylococcus aureus and manifest as weepy 
and yellow crusts.  AE usually presents with the pattern of relapses and remissions, 
aggravation by intercurrent infection, and teething or allergies. Thickness and roughness 
of affected skin may be seen in chronic cases (Buxton & Morris-Jones, 2009; Graham-
Brom & Bourke, 2007). 
 
Figure 2: Clinical Features of AE 
 
 
 
Initial onset of the skin rashes was on three months from new born.  She has developed 
asthma since she turned to 20 months.  There were redness and rashes on her face, cheeks and 
forehead with intense itchiness.  The photo was taken by Sherman Gu when the girl was six 
months old. 
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2.6 Diagnosis of AE 
Distinguishing AE from other forms of eczematous dermatitis is not always 
easy.  There are three common diagnostic guidelines for determination of AE for the 
purpose of research and clinical studies.  They are the Hanifin’s criteria (J. M. Hanifin 
& Raika, 1980), the U.K. Working Party’s diagnostic criteria (C. Charman, Chambers, 
& Williams, 2003; H. C. Williams, et al., 1994) and the American Academy of 
Dermatology (AAD) clinical criteria for AE (Eichenfield, Hanifin, Luger, Stevens, & 
Pride, 2003). 
 
2.6.1 Hanifin’s Criteria for Diagnosis of AE 
Based on their clinical studies and experience, Hanifin and Rajka established the 
first diagnostic guidelines for AE in 1980.  These include major and minor criteria.  At 
least three or more of the following major criteria should be present and plus three or 
more of the minor criteria in order to diagnose AE. 
a) Hanifin’s major criteria for diagnosis of AE 
• Skin itching  
• Typical dermatitis or eczema which has a history of relapses 
• Typical distribution of the skin rashes: facial and outer aspect of arms and 
legs in infants and children, and lichenous rashes on the flexural areas of the 
body like elbows, behind knees etc.  
• The patient or any of the family members suffering from atopy (allergic 
diseases) such as asthma, nasal allergy or atopic eczema. 
b) Hanifin’s minor criteria for diagnosis of AE 
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In addition to the major diagnostic criteria above, three or more of the 
following 15 minor criteria should also be present. 
• Dry skin  
• Cataract: anterior subcapsular- due to application of steroids near eyes 
•  Lip dermatitis  
• Recurrent eye inflammation and irritation 
• Face: pale, red  
• Food intolerance  
• Hand eczema  
• Elevated IgE levels  
• Immediate type 1 skin test reactivity  
• Recurrent infections  
• Itching on sweating  
• Pityriasis alba  
• White patches on the face and exposed area, showing mild scaling  
• White dermographism: on stroking, skin becomes white and raised, instead 
of red line as in normal people  
• Keratinous: cone shaped cornea seen between 20-40 years of age in very 
severe cases of atopic eczema.  Others like Keratosis pilaris (hair follicle 
oriented hard bumps), nipple dermatitis, dark eye circles, wool intolerance, 
linear marks on the palms etc.  
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2.6.2 U. K. Working Party Diagnostic Criteria for AE 
As Hanifin’s diagnostic criteria involve eye’s conditions which have to be 
assessed by an ophthalmologist or conditions need to be assessed by a specialist, a 
working group of 13 dermatologists, two family medical practitioners and a 
paediatrician from the United Kingdom was assembled with the aim of developing a 
minimum list of reliable discriminators for diagnosis of AE.  In order to qualify as a 
case of AE with the U.K. Working Party’s diagnostic criteria, the person must have an 
itchy skin condition in the last 12 months plus three or more of the following conditions:  
• Onset under the age of two (not used in children under four years old);  
• History of flexural involvement  
• History of a pruritic skin condition  
• Personal history of other atopic disease such as asthma (in children aged 
under four years old, history of atopic disease in a first degree relative may 
be included)   
• Visible flexural dermatitis. 
 
2.6.3 AAD Clinical Criteria of AE: 
AAD Consensus Conference on Atopic Dermatitis was held in 2001 and its 
report was published in 2003.  AE is considered as a syndrome rather than a disease.  Its 
clinical diagnostic criteria are: 
a) Essential features (must be present)   
• Pruritus  
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• Eczema (acute, subacute or chronic) with typical morphology and 
age-specific pattern 
• Chronic or relapsing history. 
b) Important features (seen in most cases, adding support to the diagnosis) 
• Early age at onset  
• Personal and/or family history of atopy and IgE reactivity  
• Xerosis. 
c) Associated features (these clinical associations help diagnosis of AE but 
are too non-specific to be used for defining or detecting AE for research 
or epidemiologic studies) 
• Atypical vascular responses  
• Keratosis pilaris/hyperlinear palms/ichthyosis  
• Ocular/periorbital changes and Perifollicular accentuation 
/lichenification/prurigo legions.  
 
2.7 Assessment of Severity for AE 
Because there is lack of biological and pathological criteria i.e. lack of 
quantitative parameter, diagnosis of AE essentially relies on its clinical manifestations.  
In addition to establishment of the diagnosis, a reliable assessment system is 
fundamental for clinicians to verify the severity, the course and outcomes of treatment 
for AE.  Followings are outlines of published and validated scoring system for 
evaluation of severity of AE.  They have been considered the most commonly used 
scores and adopted for different clinical trials of AE (C. Charman, et al., 2003). 
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2.7.1  Scoring Atopic Dermatitis (SCORAD) 
SCORAD was published by a task force of 10 European experts in 1993 (Stalder 
& Taieb, 1993).  SCORAD combines the objective (extent and intensity of the lesions) 
and subjective (daytime pruritus and sleep loss) criteria.  The objective part of 
SCORAD has been validated three years after its publication (Kunz, et al., 1997).  On 
SCORAD sheet, the extent of lesions (item A) is scored by using the “Rule of nine” 
after drawing the lesions on a proposed evaluation form.  The intensity of lesions (item 
B) is recorded by grading each of the six criteria (erythema, oedema/papulation, 
oozing/crusts, excoriation, lichenification /prurigo and dryness on uninvolved area) on a 
scale from zero (absence) to three (severe).  Subjective symptoms (item C) are scored 
by Visual Analogue Scale (VAS) from zero to 10.   The maximum objective score is 83 
(the sum of A/5 + 7B/2) and the subjective score C is 20 with a total 103 of SCORAD 
(Table 1). 
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Table 1: Scoring Atopic Dermatitis Sheet  
[adapted from (Kunz, et al., 1997)] 
 
 
 
 
Based on the objective SCORAD (from zero to 83 in which the extent of lesions 
accounts for 25% and intensity of lesions for about 75% of the total objective scores 
respectively), the severity of AE can be graded into “mild AE” (< 15 on two baseline 
measurements at a minimum interval of two weeks), “moderate AE” (between 15 and 
40 on two baseline measurements at a minimum interval of two weeks) and “severe 
AE” (> 40 on two baseline measurements at a minimum interval of two weeks).  
  
 
 17 
2.7.2  Eczema Area and Severity Index (EASI) 
As SCORAD is a complex and comprehensive system which is designed for 
pediatric patients; it is believed not efficient for quick assessment of AE for a busy 
clinical setting.  EASI was designed and validated in 2001 based on modifying general 
scheme used in Psoriasis Area and Severity Index (J. M. Hanifin, et al., 2001). 
In EASI, body is divided into four regions:  
• Head and neck (H)  
• Upper limbs (UL)  
• Trunk (T)  
• Lower limbs (LL).   
Firstly, the intensity of erythema (E), induration/population (I), excoriation (Ex) 
and lichenification (L) of a representative area of eczema are assessed as none (0), mild 
(1), moderate (2) and severe (3) by using a Four-point scale.  Half scores are accepted. 
Secondly, the approximate percentage affected region is calculated respectively.  In 
each region, the area is expressed from zero to six as nil (0), 1-9% (1), 10-29% (2), 30-
49% (3), 50-69% (4), 70-89% (5) or 90-100% (6).  Thirdly, index of proportionate areas 
of eight years of age or older were multiplied to the intensity and percentage of the 
affected area.  The index of proportionate areas on head/neck is 0.1 for eight years old 
above, 0.2 for 0 to seven years old; upper limbs is 0.2 for all age groups; trunk is 0.3 for 
all age groups and lower limbs is 0.4 for eight years old above, 0.3 for zero to seven 
years old.  Finally, the EASI is the sum of above four regions score.  
Calculation formula is as following: 
EASI = [H (E + I + Ex + L) x Area (0 – 6) x 0.1 or 0.2 for seven years old 
below]  
+ [UL (E + I + Ex + L) x Area (0 – 6) x 0.2]  
+ [T (E + I + Ex + L) x Area (0 – 6) x 0.3]  
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+ [LL (E + I + Ex + L) x Area (0 – 6) x 0.4 or 0.3 for seven years old below] 
Rank of EASI score is from 0 (no disease) to maximum of 72 (maximal disease). 
Table 2 summaries calculations for patients with eight years of age and older in 
EASI.  
 
Table 2: Eczema Area and Severity Index 
[adapted from (J. M. Hanifin, et al., 2001)] 
 
Eczema Area and Severity Index: calculation for patients 8 years of age and older1 
 Body region  EASI Score2,3  
 Head/Neck (H)  (E+I+Ex+L) x Area x 0.1 
 Upper limbs (UL) (E+I+Ex+L) x Area x 0.2 
 Trunk (T)  (E+I+Ex+L) x Area x 0.3 
Lower limbs (LL) (E+I+Ex+L) x Area x 0.4 
EASI =   Sum of the above 4 body region scores 
 Note: 1For children aged 0-7 years, proportionate areas were head/neck, 20%; 
 Upper limbs, 20%; trunk 30%; and lower limbs, 30%. 
 
2E=Erythema, I=induration/papulation, Ex=excoriation, L=lichenification. 
 
3Where area is defined on a 7-point ordinal scale: 0=no eruption; 1 ≤ 10%; 
 2 ≤ 10-29%; 3 ≤ 30-49%; 4 ≤ 50-69%; 5 ≤ 70-89%; and 6 ≥ 90-100%. 
 
 
Below is an example of EASI calculation: 
A three years old child has an acute flare-up of atopic eczema. The flare-up 
affects limb flexures, and the child's trunk is also rather pink and dry.  Less than 
10% of the arms, around 60% of the trunk and between 10 and 29% of the lower 
limbs are affected. 
• The head and neck intensity score is nil, as it is not affected. H is 0 
• The eczema in the elbow flexure is moderately red, mildly thickened, 
moderately scratched but not lichenified: UL (2 + 1 + 2 + 0) x 1 x 0.2.  UL is 1 
• On the trunk it is mildly red, mildly thickened and not scratched or lichenified: T 
(1 + 1 + 0 + 0) x 4 x 0.3. T is 2.4  
• The eczema behind the knees is severely red, severely thickened, severely 
scratched and mildly lichenified: LL (3 + 3 + 3 + 1) x 2 x 0.3.  LL is 6 
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• Total EASI is H + UL + T + LL = 9.4. 
 
2.7.3 Six Area, Six Sign Atopic Dermatitis Severity Score (SASSAD) 
SASSAD aims to provide a simple and effective system for recording and 
monitoring disease activity in AE (Berth-Jones, 1996).  The score is obtained by six 
clinical signs of disease intensity (erythema, exudation, excoriation, dryness, cracking 
and lichenification).  Each on a scale of zero (absent), one (mild), two (moderate) and 
three (severe) and measured at six defined body regions (arms, hands, legs, feet, trunk, 
head and neck) with a maximum score of 108.  It has been validated by different clinical 
trials of AE;  however, its reliability is in doubt as the score is subject to significant 
inter-observer variation (C. R. Charman, Venn, & Williams, 2002). 
 
2.8 Assessment of Quality of Life  
Besides the scoring systems for measurement of severity of the condition, QoL 
questionnaires have been created for assessment of clinical outcome and impact on QoL 
of dermatological conditions such as AE, psoriasis and generalised pruritus.  It has been 
shown these three conditions have a greater impact on QoL than acne, basal cell 
carcinomas and viral warts based on the scores of Dermatology Life Quality Index 
(DLQI) (Finlay & Khan, 1994).  DLQI has been described in over 500 publications 
including 30 multinational studies since it has been developed and validated.  It is the 
most frequently used instrument as an endpoint in RCTs in dermatology.  The 
children’s DLQI (CDLQI) was initially validated and used for children with skin 
disorders in 1995 (M. S. Lewis-Jones & Finlay, 1995).  The Infant’s Dermatitis Quality 
of Life (IDQOL) was validated in 2001 (M.S. Lewis-Jones, Finlay, & Dykes, 2001).  A 
specifically designed questionnaire to measure QoL in adults with AE named as Quality 
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of Life Index for Atopic Dermatitis (QoLIAD) was established in 2003 (Whalley, et al., 
2004).  It contains 25 items of the QoL index for AE.  The items vary from “worry 
about the appearance”, “no self-confidence” to “worry about meeting people”.  Each 
item scores from zero to one and maximum score is 25.  The higher the score of 
QoLIAD, the lower the QoL is indicated. 
 
2.9 Treatment for AE 
Currently, topical application of emollients for management of mild AE is 
considered one of the first-line therapies for protection and maintenance of skin barrier. 
Nevertheless, there is no sufficient evidence to support the recommendations of 
emollients for treatment of AE (Hoare, Li, Po, & Williams, 2000).  For moderate and 
severe AE, oral or topical administration of corticosteroids is the standard first-line 
therapy, although these treatments are not always satisfactory.  In addition, 
corticosteroids are associated with certain adverse effects, such as skin thinning if used 
for too long or in too strong a concentration for sensitive sites such as the face where the 
skin is naturally thinner and the long-term application of corticosteroids has been a great 
concern to patients and the healthcare professionals (J.M. Hanifin, et al., 2004).   
In the past decade, there have been new prescribed medicines such as tacrolimus 
and pimecrolimus, montelukast and zafirlukast (leukotriene receptor antagonists) 
available as second-line therapy (Yanase & David-Bajar, 2001).  Other therapies such as 
wrapping the eczematous lesions with silver-coated textiles (Gauger, Mempel, & 
Schekatz, 2003), and patient education programs (Schnopp, Groer, & Ring, 2003) have 
also been introduced for management of AE.  However, concerns of long-term safety of 
the new medicines, a potential link between TIMs and cancer (Centre for Drug 
Evaluation and Research, 2005), and possible silver absorption still remain 
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(Mohrenschlager, et al., 2006).  As a result, many AE sufferers also used 
complementary and alternative medicine approaches including CHM for the 
management of AE  (Lee & Bielory, 2010). 
 
2.10 Comments 
As there is no specific laboratory test to determine AE, Hanifin’s criteria for 
diagnosis of AE were the first attempt to define the condition clinically.  Some 
associated conditions listed on Hanifin’s minor criteria such as pityriasis alba, cataract 
and keratinous cornea need to be assessed by a dermatologist or an ophthalmologist, 
thus simplified diagnostic criteria were setup in the United Kingdom and the United 
States.  The terms of AE or AD are synonymous, AE is frequently used in the UK and 
AD is more popular in the USA.  Diagnostic criteria of the condition in the U.K. 
Working Party and ADD cover the essential clinical features of AE for establishment of 
a diagnosis.  However, the U.K. Working Party’s diagnostic criteria do not include the 
children with age of 12 months or less.   For this group of AE sufferers, they are often 
diagnosed with “infantile eczema” by clinicians.  It has been debated whether infantile 
eczema or childhood eczema and children with AE is the same condition.  The word 
“atopic” simply indicates that AE is very often associated with “atopy”, and separates 
this condition from other type of eczema such as primary irritant eczema, contact 
allergic eczema and so on.  Owing to the fact that onset of AE is usually in early age 
(under two years old), exogenous factors sometimes are hardly identified for the 
relapses of the condition, infantile eczema or childhood eczema is often considered as 
the same condition of children with AE (Simpson & Hanifin, 2006). 
For purpose of quantitative analysis and evaluation of severity of AE, scoring 
systems were developed and validated.  These included SCORAD, EASI and SASSAD.  
SCORAD is one of the most frequent instruments for assessment of severity of AE 
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found in published trials.  As skin disorders have an impact on the patients’ lives in 
aspects of psychological well-being, social functioning and daily activities, 
questionnaires of QoL also have been used for outcome measures in studies of RCTs.   
Although there is no evidence to support the benefit of application of emollient 
for AE, emollient is still being used as one the first-line therapies.  AE is not cured with 
either oral and/or topical administration of steroid.  Side-effects of steroid such as 
thinning of the skin have been the concern for patients and health care providers.  TIMs 
or calcineurin inhibitors are recommended as second-line therapy only if the first-line 
therapies do not sufficiently control the symptoms and signs of AE, and their safety in 
long term is still in doubt.  Consequently, complementary and alternative medicine 
including CM is another option for management of AE.  
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Section II: Chinese Medicine Perspective 
 
 
2.11 CM Definition and Diagnosis of AE  
Although there was no such terminology of AE in ancient CM classical 
literature, details of “Wind of the four fossae (Si Wan Feng 四弯风) and “Milk-tinea” 
(Nai Xuan奶癣) have been recorded.   A CM diagnosis of AE or infantile eczema is 
based on its clinical manifestations and period of eruption of skin rashes.  A most 
typical form of AE presents on face with red and inflamed skin associated with intense 
itching.  As time goes by, the neck, trunk and extensor surfaces of the limbs are affected 
and finally the flexural surfaces of the extremities such as antecubital and popliteal 
fossae become involved.  Similar descriptions of the symptoms and signs were found on 
A Comprehensive Summary of Surgery (Wai Ke Da Cheng 《外科大成》) in 1665.  It 
said: “Wind of the four fossae (Si Wan Feng), it shows up on the fossae of the legs and 
ankles with relapse monthly.  It looks like a tinea with intolerant itchiness; it becomes a 
sore after scratching.”  The earliest descriptions of infantile eczema were seen on the 
Chapter of Pediatric Miscellaneous Diseases, General Treatise on the Causes and 
Symptoms of Diseases (Zhu Bing Yuan Hou Lun《诸病源候论》) in year 610.  It said: 
“On the face of a child, it shows squamous and dry skin; it is called milk-tinea.”  On a 
monograph of CM surgery Orthodox Manual of Surgery (Wai Ke Zheng Zong 《外科
正宗》) in 1617, it quoted: “Milk-tinea is resulted from parents who are indulgent to 
spicy and deep fried food.  The heat pathogen is then transmitted to the child.  Skin 
lesions are seen on head and face and all over the body surface with discharges, 
insomnia, restlessness and intolerant itchiness.” On the Chapter of Experimental 
Therapy in Pomes in Surgery, Golden Rules of Medicine (Yi Zong Jin Jian 《医宗金
鉴》), a royal text book of CM in 1739, it noted: “(the skin lesion) appears on vertex of 
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a child, or on the eyebrows, it is also called milk-tinea.  It starts with itchiness and 
white scales and it looks like tinea….” 
Definition of “Wind of the four fossae” (Si Wan Feng) or “Milk-tinea” in CM 
correlates to AE or infantile eczema in conventional medicine based on the comparison 
of literature records of CM and the descriptions of clinical features in conventional 
medicine.  Therefore, Si Wan Feng and Milk-tinea in CM were officially defined as AE 
and infantile eczema respectively in “Criteria of Diagnosis and Therapeutic Effect of 
Disease and Syndromes in Traditional Chinese Medicine” issued by the State 
Administration of Traditional Chinese Medicine, China (SATCM, 1994).  
 
2.12 CM Aetiology and Pathogenesis of AE  
CHM has been used for treatment of AE or infantile eczema in the form of oral 
and/or topical administrations for years based on CM aetiology, pathogeneses and 
diagnosis of AE (D. C. Chen & Xuan, 2001).  From a CM point of view, aetiology and 
pathogeneses of AE or infantile eczema are constitutional insufficiency of the Lung and 
Spleen.  The disease is induced by invasion or transmission of Wind, Dampness and 
Heat pathogens to the skin.  Long standing of relapses and remissions may lead to 
damage of Yin and body fluids.  
Constitutional insufficiency of the qi in Lung and Spleen presents with 
symptoms and signs of skin dryness and itchiness in AE patient.  Skin is dominated by 
the Lung. Insufficiency of the Lung means that the Lung qi fails to distribute body 
fluids on the surface of the body which results in dryness and itchiness of the skin.  A 
deficient Spleen slows down its function of transportation and transformation of water 
and nutrients and leads to deficiency of qi and blood which makes the skin dry and 
squamous.  Parent who was indulgent in spicy and deep-fried food during pregnancy 
could generate Dampness-heat which could be passed on to the baby to become fetal 
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toxin (Tai Du 胎毒).  Dampness-heat may be transferred to the skin, or there may be 
contraction of external Wind, or Dampness-heat. They could present with various 
clinical features of itchiness (Wind predominant), swelling (oedema), weepiness 
(Dampness predominant), and yellow crusts (Heat predominant).  Damage of Yin and 
body fluids may manifest as skin thickening (lichenification) and dryness of the skin 
(Xu, 2004).  Based on aetiology, pathogeneses and different clinical manifestations of 
AE, the condition can be subcategorised into three syndromes including Accumulation 
of interior Damp-heat, Spleen deficiency with excess Dampness, and Yin deficiency 
with blood dryness.  Chinese herbs are prescribed accordingly (G. T. Chen & Yang, 
1991). 
 
2.13 CHM Treatment for AE 
 CHM can be administrated via oral intake or topical application or in 
combination of both for treatment of AE.  
 
2.13.1 Oral Application of CHMs for AE 
a) Accumulation of Interior Damp-heat 
i. Clinical features: 
Typical AE skin symptoms and signs plus constipations, deep-yellow 
coloured urine, red tongue and rapid pulse. 
ii. Principle of treatment:  
Eliminate dampness and clear heat pathogen 
iii. Formula:  
Modified Expel Wind and Guide Redness Decoction (Xiao Feng Dao 
Chi Tang 消风导赤汤) 
iv. Prescription: 
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Sheng Di Huang (Radix Rehmanniae Glutinosae) 6g 
Jin Yin Hua (Flos Lonicerae) 6g 
Bo He (Herba Menthae Haplocalycis) 6g 
Huang Lian (Rhizoma Coptidis) 6g 
Chuan Mu Tong (Caulis Clematidis Armandii) 4g 
Fu Ling (Sclerotium Poriae Cocos) 6g 
Bai Xian Pi (Cortex Dictamni Dasycarpi Radicis) 6g 
Sheng Gan Cao (Radix Glycyrrhizae) 3g 
Deng Xin Cao (Medulla Junci Effusi) 3g 
v. Explanation: 
Sheng Di Huang (Radix Rehmanniae Glutinosae) cools blood and clears 
heat.  Jin Yin Hua (Flos Lonicerae) and Bo He (Herba Menthae 
Haplocalycis) release exterior.  Huang Lian (Rhizoma Coptidis) dries the 
dampness and clears interior heat.  Chuan Mu Tong (Caulis Clematidis 
Armandii) eliminates damp-heat by promoting diuresis.  Fu Ling 
(Sclerotium Poriae Cocos) strengthens the Spleen and eliminates 
dampness.  Bai Xian Pi (Cortex Dictamni Dasycarpi Radicis) eliminates 
dampness and stops itchiness.  Sheng Gan Cao (Radix Glycyrrhizae) and 
Deng Xin Cao (Medulla Junci Effusi) assist Chuan Mu Tong (Caulis 
Clematidis Armandii) to promote diuresis and guide heat downwards.  
b) Spleen Deficiency with Excess Dampness 
i. Clinical features: 
Typical AE symptoms and signs plus sallow complexion, 
listlessness, fatigue, poor appetite, loose stools or diarrhea, pale 
tongue and slippery or soft pulse. 
ii. Principle of treatment:  
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Strengthen the Spleen and eliminate dampness 
iii. Formula:  
• Child Eliminate Dampness Decoction for Infantile Eczema (Xiao 
Er Hua Shi Tang 小儿化湿汤) 
• Eliminate Dampness in the Stomach with Sclerotium Poriae 
Cocos Decoction (Chu Shi Wei Ling Tang 除湿胃苓汤) 
iv. Prescription: 
• Child Eliminate Dampness Decoction for Infants (Xiao Er 
Hua Shi Tang 小儿化湿汤) 
Cang Zhu (Rhizoma Atractylodis) 6g 
Fu Ling (Sclerotium Poriae Cocos) 6g 
Chen Pi (Pericarpium Citri Reticulatae) 6g 
Chao Mai Ya (Fructus Hordei Vulgaris Germinatus, stir-fried) 
6g 
Ze Xie (Rhizoma Alsmatis Orientalis) 6g 
Hua Shi (Talcum) 12g 
Sheng Gan Cao (Radix Glycyrrhizae) 2g 
• Eliminate Dampness in the Stomach with Sclerotium Poriae 
Cocos Decoction (Chu Shi Wei Ling Tang 除湿胃苓汤) 
Cang Zhu (Rhizoma Atractylodis) 12g 
Hou Pu (Cortes Magnoliae Officinalis) 10g 
Chen Pi (Pericarpium Citri Reticulatae) 8g 
Zhu Ling (Polypours) 12g 
Ze Xie (Rhizoma Alsmatis Orientalis) 12g 
Fu Ling (Sclerotium Poriae Cocos) 12g 
Bai Zhu (Rhizoma Atractylodis) 12g 
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Hua Shi (Talcum) 12g 
Fang Feng (Radix Ledebouriellae Divaricatae) 12g 
Chuan Mu Tong (Caulis Clematidis Armandii) 10g 
Rou Gui (Cortex Cinnamomi) 3g 
Zhi Zi (Fructus Gardeniae) 10g 
Deng Xin Cao (Medulla Junci Effusi) 6g 
Sheng Gan Cao (Radix Glycyrrhizae) 2g 
v. Explanation: 
Child Eliminate Dampness Decoction for Infants (Xiao Er Hua 
Shi Tang 小儿化湿汤) 
Cang Zhu (Rhizoma Atractylodis) and Chen Pi (Pericarpium Citri 
Reticulatae) dry dampness and regulate qi.  Fu Ling (Sclerotium 
Poriae Cocos) strengthens the Spleen and promotes diuresis.  
Chao Mai Ya (Fructus Hordei Vulgaris Germinatus, stir-fried) 
strengths the Stomach and aids digestion.  Ze Xie (Rhizoma 
Alsmatis Orientalis) eliminates dampness by promoting diuresis.  
Hua Shi (Talcum) and Sheng Gan Cao (Radix Glycyrrhizae) are 
ingredients of Six-one Powder (Liu Yi San 六一散 ) that 
eliminates summer-heat and promotes diuresis. 
Eliminate Dampness in the Stomach with Sclerotium Poriae 
Cocos Decoction (Chu Shi Wei Ling Tang 除湿胃苓汤) 
The four herbs, Cang Zhu (Rhizoma Atractylodis), Hou Pu 
(Cortes Magnoliae Officinalis), Chen Pi (Pericarpium Citri 
Reticulatae) and Sheng Gan Cao (Radix Glycyrrhizae) are the 
ingredients of the formula, Calming the Stomach Powder (Ping 
Wei San 平胃散) which has the function of drying dampness, 
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regulating qi and harmonising the Spleen and Stomach.  Zhu Ling 
(Polypours), Ze Xie (Rhizoma Alsmatis Orientalis) and Chuan 
Mu Tong (Caulis Clematidis Armandii) eliminate dampness by 
promoting diuresis.  Fu Ling (Sclerotium Poriae Cocos) and Bai 
Zhu (Rhizoma Atractylodis) strengthen the Spleen and eliminate 
dampness.  Hua Shi (Talcum), Zhi Zi (Fructus Gardeniae) and 
Deng Xin Cao (Medulla Junci Effusi) clear heat and promote 
diuresis.  Fang Feng (Radix Ledebouriellae Divaricatae) expels 
wind and stops itch.  Rou Gui (Cortex Cinnamomi) balances the 
cold property of other herbs. 
c) Yin Deficiency with Blood Dryness 
i. Clinical features: 
Typical AE symptoms and signs plus dry and thickened skin with 
scaling, red or dark red tongue body with scanty silver, peeled tongue 
coating, deep and thready pulse. 
ii. Principle of treatment: 
Nourish Yin, replenish blood and moisten dryness 
iii. Formula: 
Modified Radix Rehmanniae Glutinosae Decoction (Di Huang Yin 
Zi 地黄饮子) 
iv. Prescription: 
Shu Di Huang (Radix Rehmanniae Glutinosae Preparata) 30g 
Dang Gui (Radix Angelicae Sinensis) 12g 
He Shou Wu (Radix Ploygoni Multiflori) 15g 
Sheng Di Huang (Radix Rehmanniae Glutinosae) 12g 
Xuan Shen (Radix Scrophulariae Ningpoensis) 12g 
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Mu Dan Pi (Cortex Moutan Radicis) 12g 
Hong Hua (Flos Carthami Tinctorii) 12g 
Jiang Can (Bombyx Batryticatus) 8g 
Bai Ji Li (Fructus Tribuli Terrestris) 12g 
Sheng Gan Cao (Radix Glycyrrhizae) 6g 
v. Explanation: 
Shu Di Huang (Radix Rehmanniae Glutinosae Preparata), Dang Gui 
(Radix Angelicae Sinensis) and He Shou Wu (Radix Ploygoni 
Multiflori) replenish blood.  Sheng Di Huang (Radix Rehmanniae 
Glutinosae) and Xuan Shen (Radix Scrophulariae Ningpoensis) 
nourish Yin.  Mu Dan Pi (Cortex Moutan Radicis), Hong Hua (Flos 
Carthami Tinctorii) and Jiang Can (Bombyx Batryticatus) invigorate 
blood circulation and open channels.  Bai Ji Li (Fructus Tribuli 
Terrestris) expels wind and stops itch. Sheng Gan Cao (Radix 
Glycyrrhizae) harmonises actions of other herbs. 
 
2.13.2 Topical Application of CHM for AE 
Unlike oral application of CHM, topical application of CHM is used based on 
different skin lesions rather than syndrome identification (Gu & Huang, 1993). 
Formulae listed below in the form of topical administration are recommended 
for AE or infantile eczema: 
a. Herbal ointments: 
i. Formula: 
Indigo Naturalis Ointment (Qing Dai Gao 青黛膏)  
ii. Prescription: 
Qing Dai (Indigo Naturalis) powder 75g 
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Vaseline 300g 
iii. Function: 
Clear heat and toxin, moisten skin and stop itchiness. 
iv. Indication: 
Children aged between 1 to 6 months with eczema. 
b. Herbal powder: 
i. Formula: 
Indigo Naturalis Powder (Qing Dai San 青黛散) 
ii. Prescription: 
Qing Dai (Indigo Naturalis) 60g 
Shi Gao (Gypsum Fibrosum) 120g 
Hua Shi (Talcum) 120g 
Huang Bai (Cortex Phellodendri) 60g 
iii. Function: 
Clear heat and toxin, astringe and stop itchiness. 
iv. Indication: 
Children in age group of 12 months and above with AE. 
 
2.14 RCTs for Oral Administration of CHM for AE 
Zhang and his team conducted a Cochrane systematic review on RCTs using 
oral Zemaphyte for treatment of AE (Zhang, et al., 2004).  Zemaphyte was a 
commercial mixture with 10 Chinese medicinal herbs.  It has been no longer available 
on market since 2004 as the manufacturer was unable to obtain license to produce the 
mixture.  The product was composed of Fang Feng (Ledebouriella Seseloides), Wei 
Ling Cai (Potentilla Chinensis), Chuan Mu Tong (Clematis Armandii), Sheng Di Huang 
(Rehmannia Glutinosa), Shao Yao (Paeonia Lactiora), Dan Zhu Ye (Lophatherum 
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Gracile), Bai Xian Pi (Dictamnus Dasycarpus), Bai Ji Li (Tribulus Terrestris), Gan Cao 
(Glycyrrhiza Uralensisand), and Jing Jie (Schizonepeta Tenuifolia).  Three RCTs using 
Zemaphyte for adults or children with AE were conducted in 1990’s and year 2000 in 
UK and another trial with the same products was completed in Hong Kong in year 1999.  
Three trials were randomised placebo controlled cross-over designs, consisting of two 
phases with eight weeks for each phase, and assessing the Zemaphyte with inert plants 
as placebo.  There were total 159 participants aged from one to 60 years in those 
included trials.  The drop-out rates ranged from 7.5% to 22.5% and no trial used 
intention-to-treat (ITT) analysis.  In two of these three trials the reduction in erythema 
and skin damage was greater in the intervention group than in placebo, and participants 
showed improvement in sleeping and expressed a preference for Zemaphyte.  One trial 
also reported that participants in the intervention group experienced less itchiness.  But 
one trial reported there were no differences between the Zemaphyte and placebo.  A 
fourth trial in year 1999 conducted in Hong Kong was an open-label design to evaluate 
Zemaphyte in a freeze dried granules form with the same ingredients of Zemaphyte in 
herbal form in 18 participants with AE.  There was a similar effect in the two different 
forms of preparation of the product.  The reviewers concluded that Chinese herbal 
mixtures may be effective in the treatment of AE.  The reviewers also pointed out that 
there were only four small, and low quality RCTs of the same product identified in their 
review and the clinical outcomes were heterogeneous.  
Another randomised, double-blind, placebo-controlled clinical trial using an oral 
CHMs concoction was published in 2007 (K. Hon, et al., 2007).  A total of 85 patients 
aged from five to 21 years with moderate-to-severe AE (objective SCORAD > 15) were 
recruited in February 2004 to July 2005.  The authors claimed there was a significant 
improvement in QoL with measurement of the CDLQI in the intervention group 
compared with patients receiving placebo at the end of the three-month treatment and 
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four weeks after stopping treatment (p = .008 and .059 respectively).  Number of days 
of using topical corticosteroid was also reduced in intervention group (p = .003) in 
comparison with the placebo group (p = .289).  The total amount of topical 
corticosteroid used was significantly decreased by one-third in the intervention group at 
month four of the trial in the intervention group in comparison of what in the placebo 
group (p = .024).  Although SCORAD score fell from 58.3 to 49.7 in the intervention 
group (N = 42; p = .003) in comparison of baseline, there was no significant difference 
compared to the placebo group which was also observed a reduction of the score from 
56.9 to 46.9 (N = 43; p = .001).  The concoction contained five Chinese medicinal 
herbs: Jin Yin Hua (Flos Lonicerae) 2g, Bo He (Herba Menthae) 1g, Mu Dan Pi (Cortex 
Moutan) 2g, Cang Zhu (Rhizoma Atractylodis) 2g, and Huang Bai (Cortex 
Phellodendri) 2g  with a total of 9 grams of raw herbs.  Dosage of CHM was three 
capsules of the formula twice daily for a period of 12 weeks in the trial.  The 
investigators concluded that the CHM preparation is effective in improving QoL and 
reducing topical corticosteroid use in children with moderate-to-severe AE. 
 
2.15 Comments 
A syndrome (Zheng 证) in CM is a pathological conclusion of a disease, in which 
its causes, features e.g. cold or heat type and location (interior or exterior) in a certain 
period of time are included.  In the framework of holistic conception, identification of a 
syndrome is more radical than that of a disease.  A disease (Bing 病) is a conclusion of 
full prognosis of a disorder in the body including characteristics (symptoms and signs) 
and rules of a disorder in CM point of view (Deng & Guo, 1987).  For instance, “Wind 
of the four fossae (Si Wan Feng )” is a disease in CM.  It then can be subcategorised 
into different syndromes such as: Accumulation of interior damp-heat, Spleen 
deficiency with excess dampness and Yin deficiency with blood dryness according to 
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various associated symptoms and signs manifested on an individual.  Pertained to the 
principle of “Determination of treatment based on syndrome identification (Bian Zheng 
Lun Zhi 辨证论治 )”, a single disease of “Wind of the four fossae” should be 
individually treated with different Chinese herbal formulae as outlined on Section 
2.13.1.   Definition of “Wind of the four fossae” in CM diagnosis is not completely 
covering the main clinical features of AE as its description was only for the skin lesions 
on the legs and ankles with monthly relapse.  Further, syndrome identification of “Wind 
of the four fossae” relies on those non-specific symptoms and signs such as bowel 
movements such as constipations or diarrhoea, colour of urine, tongue and pulse 
readings.  The accuracy of the syndrome identification is in doubt as it is determined by 
those non-specific symptoms and signs which could be seen in other diseases and vary 
from time to time during the course of a disease.   Inconsistence and bias of syndrome 
identification are also inevitable and substantial as the collection of those symptoms and 
signs mostly depend on clinician’s personal experience or clinical skills.  As a 
syndrome identification is determined on those non-specific symptoms and signs 
appearing during the process of a disease, a disease in CM like “Wind of the four 
fossae” or AE could be further subcategorised into different syndromes based on 
clinician’s assessment criteria.  Consequently the disease could be treated with different 
Chinese herbs (Zhou & Li, 2008).  Thus, there is a need for evaluation of effectiveness 
of CHM for AE as well as establishment of validated Chinese medicine syndromes of 
AE based on evidence with statistical significance.  
In summary, although the Cochrane systematic review of CHM for AE 
conducted by Zhang and his team in 2004 found that a certain CHM product might be 
efficacious for AE; results among the included trials were conflicting.  RCT conducted 
by Hon and his colleagues in 2007 demonstrated that the CHM concoction was effective 
in improving QoL and reducing usage of topical steroid in children.  In regarding the 
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AE skin lesion, the treatment intervention used in Hon’s report did not show significant 
difference to what in the controlled group.   Both the Cochrane systematic review and 
Hon’s RCT only dealt with oral applications of CHM for AE.  Scientific evidence of 
efficacy and safety of topical application of CHM for AE is absent; therefore there is a 
need to seek for such evidence through a systematic review. 
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Chapter 3  Methods  
 
 
 
This chapter describes the methodology used in the systematic review and 
development of a protocol for a pilot randomised double-blinded placebo-controlled 
clinical trial for topical application of CHM for AE.  
Section I: Methodology of Systematic Review  
 
This systematic review follows the methods specified in the Cochrane 
Handbook for Systematic Reviews of Interventions 5 (the Handbook) (The Cochrane 
Collaboration, 2008). 
 
3.1 Search Strategies 
 
3.1.1 Electronic Searches 
The following electronic databases were searched in February, March and 
October 2008 when this program was conducted for identifying studies to be included in 
the review: 
• Cochrane Skin Group Ongoing Skin Trials Register (up to 2008) 
• The Cochrane Central Register of Controlled Trials (CENTRAL) (up to 
2008) 
• AMED (1985 – 2008)  
• CINAHL (EBSCO) (1982-2008)  
• HERBMED (1998 – 2008) 
• LILACS (1982 – 2008)  
• mRCT (1998 – 2008)  
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• ProQuest (1938 – 2008) 
• PubMed (1966-2008)  
• SCOPUS (1996 – 2008).  
In addition, the following Chinese databases were searched: 
• VIP Information (cqvip.com) (1989-2008)  
• China National Knowledge Infrastructure (cnki.net) (1979-2008) 
• Wanfang Data (wanfangdata.com.cn) (1982-2008).  
 
The sample strategies used for searching in MEDLINE (OVID) are listed as 
below: 
# 1. randomized controlled trial.pt. 
# 2. controlled clinical trial.pt. 
# 3. randomized.ab. 
# 4. placebo.ab. 
# 5. clinical trials as topic.sh. 
# 6. randomly.ab. 
# 7. trial.ti. 
# 8. #1 or #2 or #3 or #4 or #5 or #6 or #7 
# 9. (animals not (human and animals)).sh. 
#10. #8 not #9  
# 11. dermatitis/ or exp dermatitis atopic/ or exp eczema/ or exp neurodermatitis/  
# 12. besniers prurigo.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
# 13. prurigo.mp. 
# 14. exp drugs chinese herbal/ 
# 15. exp traditional medicine chinese/ 
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# 16. exp plants medicinal/ 
# 17. exp herbs/ 
# 18. herbs/ or herbs.mp. 
# 19. exp complementary medicine/ or exp complementary therapies/ 
# 20. alternative medicine.mp. 
# 21. traditional therapy.mp. 
# 22. Traditional medicine/ or traditional medicine.mp. 
# 23. alternative therapy.mp. 
# 24. #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 
# 25. #11 or #12 or #13 
# 26. #10 and #24 and #25 
Similar search strategies plus “infantile eczema” or “childhood eczema” were 
applied to other databases.   
 
3.1.2 Hand-searches 
The following CM journals and conference proceedings were hand-searched:  
• Journal of Chinese Medicine (1999-2008)  
• Chinese Journal of Integrated Traditional and Western Medicine (1995-
2008) 
• American Journal of Chinese Medicine (1995-2002)  
• Journal of Traditional Chinese Medicine (1995-2008)   
• Congress proceedings of the First World Congress on Chinese Medicine 
(Melbourne 2003)   
• Congress proceedings of the Third International Congress of Traditional 
Medicine (Toronto 2006).  
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3.1.3 Unpublished Studies 
Clinicians or dermatologists and experts in CM were contacted for unpublished 
RCTs. 
 
3.1.4 Study Selection 
Two reviewers, Sherman Gu (SG, the candidate) and Angela Yang (AY, 
supervisor) independently screened the titles and abstracts of all identified studies 
according to the inclusion and exclusion criteria.  If there was insufficient information 
in the titles or abstracts, the full text of the studies were retrieved for further information.  
Any discrepancy between the two reviewers was discussed with a third party Chun 
Guang Li (CL, senior supervisor) or Charlie Xue (CX, consultant). 
 
3.2 Inclusion and Exclusion Criteria 
 
3.2.1 Types of Studies 
All RCTs, with or without blinding, published in English or Chinese languages 
were included. For cross-over studies, only data from the first treatment phase was 
included. 
 
3.2.2 Types of Participants  
All patients with AE were considered regardless of age, gender and ethnic 
group. AE must be diagnosed according to internationally recognised criteria such as 
the Hanifin and Rajka criteria (J. M. Hanifin & Raika, 1980) or the UK refinement (H. 
C. Williams, et al., 1994) when the terms "atopic eczema" or "atopic dermatitis" were 
used in the articles.  In the absence of explicit diagnostic criteria, studies for adult 
participants diagnosed with "eczema" or "chronic eczema" were excluded.  However, 
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studies for children (new born to 16 years old) diagnosed with "eczema" by physicians 
or dermatologists were included as diagnosis of infantile eczema or childhood eczema is 
equivalent to AE as discussed on Section 2.1 of Chapter 2. 
 
3.2.3 Types of Interventions  
We included topical applications of CHM (manufactured or clinician self-
designed Chinese medicinal formulae) if they were compared with the following control 
interventions: placebo, no intervention, acupuncture, or conventional medicines (drugs). 
We excluded trials with a combination of topical and oral CHM interventions or 
a combination of topical application of CHM and drugs or a combination of topical 
application of CHM and other therapy such as acupuncture. 
 
3.2.4 Types of Outcome Measures  
RCTs were included if at least one of the following primary or secondary 
outcome measures was used: 
3.2.4.1 Primary Outcomes  
a) Percentage of trial participants with at least good or excellent 
improvement in terms of investigator score. Both short-term (within six 
weeks) and long-term (seven weeks or more) improvement were 
included. 
b) Percentage of trial participants with at least good or excellent 
improvement in terms of participants/parents self-rated score.  Both 
short-term (within six weeks) and long-term (seven weeks or more) 
improvement were included. 
3.2.4.2 Secondary Outcomes  
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a) Changes in participants/parents self-rated improvement in SCORAD, 
EASI, or SASSAD as stated in each of the trials in both short-term 
(within six weeks) and long-term (seven weeks or more) improvement. 
b) Changes in participants/parents self-rated improvement in QoL both 
short-term (within six weeks) and long-term (seven weeks or more) 
improvement. 
c) Adverse events. 
 
3.3 Data Extraction  
Data were extracted by using a data extraction form developed by the Cochrane 
Skin Group which has been modified to suit this review (Appendix 1).  Data from each 
selected study consisted of the number of events (n) and participants (N) in individual 
patient data for dichotomous data and number of participants (N), mean, and standard 
deviation (SD) for continuous data.  Extracted data also consisted of the treatment and 
controlled interventions, outcome measures and adverse events. Two reviewers SG and 
AY independently extracted the data.  When the information in the published article was 
insufficient, the investigators of the studies were contacted.   
 
3.4 Assessment of Risk of Bias of Included Studies 
SG and AY independently assessed the risk of bias of included studies with the 
items which consist of the domains of: 
a)  randomisation,  
b)  sequence generation,  
c)  allocation concealment,  
d)  blinding of participants, personnel and outcome assessors, 
e)  items of incomplete outcome data. 
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Any discrepancies between the two reviewers were resolved by the third party 
CL and CX through discussion. All corresponding authors of included studies were 
contacted by mails for clarification of the data such as study design, method of 
randomisation and statistic data when needed (Appendix 2). 
 
3.5 Data Analysis 
Meta-analyses were conducted by using the RevMan 5 software (The Cochrane 
Collaboration, 2008). 
 
3.5.1 Data Synthesis and Measures of Treatment Effect 
It was anticipated that the nature of the interventions could be quite diverse, and 
it was, therefore, unlikely that they would all estimate the same treatment effect.  
Indeed, the included studies in our review expressed different, yet related, intervention 
effects, and for this reason, we conducted a random-effects model when attempting to 
pool data from included studies.  We planned that if substantial heterogeneity was found 
(I² statistic greater than 50%), then we would explore the sources of such heterogeneity 
by rechecking the data, and by subgroup analysis based on clinical and methodological 
diversity factors. If the presence of substantial heterogeneity could not be explained, we 
would not undertake statistical pooling. 
 
3.5.2 Heterogeneity of Included Studies 
The heterogeneity of included studies was interpreted through the characteristics 
of interventions. It was assessed by using I² statistic, which describes the percentage of 
variation across studies due to heterogeneity rather than by chance. The effect size 
analysis was conducted to explore the differences between interventional groups. 
Dichotomous data were tested by Mantel-Haenszel with random-effects analysis model 
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and expressed as risk ratios (RR) with 95% confidence intervals (CI). When sufficient 
data were available, continuous data were presented as difference of means (MD) with 
95% CI when all studies used the same measurement scale or as standardised mean 
differences (SMD) with 95% CI if different scales were used to measure the same 
outcome and p < .05 was regarded as significant. 
 
3.5.3 Reporting Bias 
Reporting bias was assessed by testing funnel plot asymmetry as recommended 
on Section 10.4.3.1 of the Handbook if there were more than 10 trials included in the 
meta-analysis.  
 
3.5.4 Subgroup Analysis 
We planned to perform subgroup analyses under the heading of "Children (16 
years old or under) with AE versus Adult with AE", and "Application of Intervention 
Based on Chinese Medicine Syndrome Differentiation versus Non-individualisation 
Formula" where there are at least moderate levels of heterogeneity across the included 
studies.  We proposed to investigate the sources of heterogeneity including participant 
factors e.g. age, diagnosis, sex, race, co-morbidity, treatment factors e.g. dosage, 
formulation, and study factors e.g. concordance rates, quality of reporting, and quality 
control for the Chinese herbal preparations e.g. source, purity, preparation facilities to 
explain such differences. 
  
3.5.5 Sensitivity Analysis  
We planned to perform sensitivity analyses of the primary outcomes by 
excluding studies with high risk of bias.  Where substantial heterogeneity exists 
between studies for the primary outcome (I² statistic > 50%), sources for such 
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heterogeneity such as diagnosis of the disease, composition or dose of the herbal 
medication should be sought and explored in sensitivity analyses. 
 
3.5.6 Report of Adverse Events and Dealing with Missing Data 
We planned to report studies relating to adverse events quantitatively.  We also 
planned to apply ITT analysis to the included study if there are any missing data. 
 
3.6 Studies with Multiple Treatment Groups and Unit of Analysis Issues 
We planned to select the intervention group that is most relevant to the 
systematic review if studies involve multiple treatment groups.  
We considered unit of analysis issues if a study involves measurements on 
different body parts such as comparison of a site on one arm versus another site on the 
other arm for topical interventions. In this case, we would treat the study as a "within 
patient trial" and we would perform separate meta-analysis as appropriate.  
For cross-over trials where participants were given different treatments in 
random sequence, we planned to undertake a separate meta-analysis.  The results from 
the first treatment phase might be combined with those from the parallel trials if data are 
available, then we proposed to combine the data from included parallel studies and the 
treatment phase of included cross-over studies in the meta-analysis.  We also planned to 
include cross-over studies only if their methods were appropriate as suggested by the 
Handbook.     
 
Section II: Methodology of Protocol for a Pilot RCT 
 
A protocol for pilot randomised double-blind placebo-controlled clinical trial for 
topical application of CHM for AE was developed.  This protocol was prepared 
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according to the guidelines of Australian Clinical Trial Handbook issued by 
Therapeutic Goods Administration (TGA), Department of Health and Ageing, 
Australian Government (TGA, 2006) and follows the “Nine CONSORT Checklist Items 
For RCTs of Herbal Medicines” recommended by the Consolidated Standards of 
Reporting Trials (CONSORT) Group (Gagnier, et al., 2006).  Key elements for 
conducting a good quality RCT such as randomisation, sequence generation, allocation 
concealment, blinding methods, proper sample size, compliance with protocol, 
determination of baseline and endpoint as well as adequate outcome measures have 
been well addressed.  Details of the protocol are presented on Chapter 5. 
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Chapter 4  Results I - Systematic Review 
 
This chapter reports the findings of the systematic review which was based on 
the rigorous methodology specified in Chapter 3.  It also discusses the findings and 
makes recommendations for future research. 
 
4.1 Selection of Studies 
 
4.1.1 Search Results 
There were 164 potential studies identified. The number of studies identified 
from each database is summarised in Table 3. 
 
Table 3: Summary of Search Results 
 
Database Date of 
Search 
Number of the 
Potential Studies 
Cochrane Skin Group: Ongoing Skin 
Trials Register (up to 2008) 
08/02/2008 10 
The Cochrane Central Register Of 
Controlled Trials (CENTRAL) (up to 
2008) 
06/03/2008 12 
PubMed MEDLINE (1966-2008) 06/03/2008 17 
cqvip.com (1989-2008) 24/10/2008 68 
wanfangdata.com.cn (1982-2008) 24/10/2008 26 
cnki.net (1979-2008) 29/10/2008 31 
Total:  164 
 
 
4.1.2 Screening of Studies 
Among the potential 164 studies, 129 were excluded after screening the titles 
and abstracts with various reasons which included non-topical applications of CHM (N 
= 40), review/protocol (N = 48), non-clinical study (N = 9), treatment intervention 
combined with conventional medicines (N = 4), non-RCT (N = 13) and duplicated 
publication (N = 15).  Full texts of the rest 35 papers were retrieved and 26 studies were 
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excluded due to either absence of controlled group, or oral application of the treatment 
intervention, or topical treatment intervention combined with oral application of CHM 
or drugs or acupuncture, or non-AE study.  Of the other nine studies, we performed a 
test of meta-analysis to measure consistency of outcomes across the studies and found 
that the I² statistic was greater than 50% which indicated heterogeneity.  We then 
reassessed the data of those nine studies and found that six of them were quasi-
randomised or pseudo-randomised studies according to the definition outlined in Box 
13.4a of the Handbook.  Numbers of participant in the treatment group were much 
greater than those in the control group in those six studies.  Therefore, only three studies 
finally met the criteria and were included in this review.  Reasons for the exclusion of 
those six papers are provided in  Table 4 Characteristics of excluded studies.  The 
study selection process is shown in Figure 3. 
 
 Table 4:  Characteristics of Excluded Studies    
 
Studies  Reasons of Exclusion References 
Fu 2000  ALLOCATION: 
Quasi-randomised 
(Fu, 2000) 
He 2000 ALLOCATION: 
Quasi-randomised 
(He, Li, & Ding, 
2000) 
Li 2005 ALLOCATION: 
Quasi-randomised  
(H. M. Li, 2005) 
Lin 2002 ALLOCATION: 
Quasi-randomised 
(Lin, et al., 2002) 
Liu 2002 ALLOCATION: 
Quasi-randomised  
(W. X. Liu, 2002) 
Wang 2004  ALLOCATION: 
Quasi-randomised  
(J. F. Wang, 2004) 
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Figure 3: Flowchart of Study Selection Process 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2 Characteristics of Included Studies 
The summary of characteristics of included studies is provided in Table 5.  
Potential studies  
identified (N=164) 
Full-text  
retrieved (N=35) 
Studies excluded  
No controlled group (N=14),  
Oral application of CHM (N=6) 
Non-AE study (N=2)  
Combination of topical and oral 
application of CHM (N=2) 
Combination of topical application 
of CHM and drugs (N=1) 
Combination of topical application 
of CHM and acupuncture (N=1) 
Studies excluded 
Non-topical (N=40),  
Review/protocol (N=48),  
Non-clinical study (N=9),  
Combined with drugs (N=4),  
Non-RCT (N=13),  
Duplicated publication (N=15) 
Test for outcomes 
consistency (N=9) 
Quasi-randomised study (N=6) 
 
RCTs included for 
data analysis (N=3) 
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Table 5: Characteristics of Included Studies 
 
Sample size Intervention Study Design Setting Diagnostic criteria 
Treatment 
(N, age) 
Control 
(N, age) 
Treatment Control 
Ma 2007 Parallel 
group, 
control 
study 
Did not 
state 
Grade I: erythema with millet 
sized papules.  
Grade II: bleeding, ulcer and 
discharges.  
Grade III: crustae and 
decrustation 
CM subcategory: not stated 
38, 2 to 24 
months 
30, 2 to 24 
months 
Zi Cao oil 
Ingredients and dosage:  
Zi Cao (Radix Arnebiae) 200g, Ma 
You (Oleum Sesami) 500g. 
Route of administration:  
External application of the oil 3 to 5 
times per day 
Duration of treatment:  
7 days 
Follow-up:  
6 to 12 months after the treatment 
and there were 9 cases relapsed 
Topical usage of 
calamine lotion 3 
to 5 times daily for 
7 days. 
Follow-up: 6 to 12 
months after the 
treatment and 
there were 19 
cases relapsed 
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Nie 2002 Parallel 
group, 
control 
study 
Did not 
state 
Skin lesions such as rashes, 
papules, erythema, blisters, 
yellowish scales and crustae, 
discharges and erosion that 
distributed on face and the rest of 
the body 
CM subcategory: not stated 
160, 2 to 12 
months 
149, 2 to 12 
months 
CHM lotion 
Ingredients and dosage:  
Di Yu (Radix Sanguisorbae) 15g, 
Ma Chi Xian (Herba Portulacae) 
15g, Huang Lian (Rhizoma Coptidis) 
10g, Huang Bai (Cortex 
Phellodendri) 10g, Cang Zhu 
(Rhizoma Atractylodis) 10g, Wu Bei 
Zi (Galla Chinensis) 10g, He Zi 
(Fructus Chebulae) 10g, Ku Fan 
(processed Alumen) 10g 
Route of administration: 
External moist dressing, 30 minutes, 
once a day 
Duration of treatment:  
3 to 5 days 
Follow-up:  
68 cases with relapse.  Did not state 
when the follow-up was taken. 
Penicillin 
(150,000 to 
250,000 units/kg,) 
intramuscular 
injection, twice 
daily for 3 days. 
Topical 
application of 
cortisone creams 3 
times per day. Did 
not state how 
many days that the 
creams were used. 
Oral intake of 
chlorpheniramine 
0.35mg/kg, for 3 
days 
Follow-up: 82 
cases with relapse.  
Did not state when 
the follow-up was 
taken. 
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Yang 2007 Parallel 
group, 
control 
study 
Did not 
state 
1. Children with obesity or 
malnutrition, skin lesions such as 
rashes, erythema, blisters, 
yellowish and whitish scales and 
crustae on the cheek, face, head 
and the rest of the body; 2. 
Severe pruritus resulted to loss of 
sleep, poor appetite; 3. Skin 
lesions associated with 
discharges and erosions or 
secondary infection 
CM subcategory: not stated 
40, 1 to 24 
months 
35, 1 to 24 
months 
CHM powder 
Ingredients and dosage: 
Qing Dai (Indigo Naturalis) 200g, 
Shi Gao (Gypsum Fibrosum) 400g, 
Hua Shi (Talcum) 400g, Huang Bai 
(Cortex Phellodendri) 200g, Ku 
Shen (Radix Sophorae Flavescentis) 
200g, Lu Gan Shi (Calamina) 200g 
Route of administration:  
Applied the powder on the affected 
skin externally 3 to 4 times per day. 
Duration of treatment:  
7 to 10 days 
Follow-up:  
One case after 12 months without 
relapse 
Oral intake of 
antihistamine and 
vitamin B 
complex, calcium 
tablets. 
Did not state 
dosage of the 
controlled 
intervention. 
Did not state 
follow-up. 
 
Note: N = number of participants
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4.2.1 Types of Studies 
All three included studies (Ma 2007; Nie 2002 and Yang 2007) were 
randomised controlled parallel clinical studies with topical application of CHM for 
infantile eczema or childhood eczema.  All of them were conducted in China and 
published in Chinese.  None of them used blinding design.  No included studies were 
cross-over trials.  Descriptions of each included studies were detailed in Section 4.3. 
 
4.2.2 Types of Participants 
A total of 452 participants aged from one month to two years old and diagnosed 
with infantile eczema or childhood eczema by clinicians were recruited in these studies.  
Sample sizes of these included studies ranged from 68 to 309.  Diagnostic criteria for 
the skin condition were set by the clinicians in included studies and none of these 
studies reported exclusion criteria.  Although the studies did not use international 
recognised diagnostic criteria for AE for recruitment of participants, we included these 
studies for systematic review because their clinical diagnoses were considered to be 
equivalent to the definition of AE as described in Section 2.1, 2.10 and 2.11 of Chapter 
2, and met the inclusion criteria stated in Section 3.2.2 of Chapter 3.  None of these 
studies differentiated the condition according to the CM syndrome identifications. 
  
4.2.3 Types of Interventions 
There are three different Chinese herbal formulae used as treatment 
interventions in the three included studies. All of them used self-designed formulae (Zi 
Ni Fang 自拟方).  One study (Ma 2007) applied CHM oil topically.  One study (Yang 
2007) used CHM powder directly on the affected areas and the other one (Nie 2002) 
employed moist dressing of CHM on the surface of the skin lesions.  
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A total of 15 Chinese herbs with botanical and mineral origins including Zi Cao 
(Radix Arnebiae), Ma You (Oleum Sesami), Di Yu (Radix Sanguisorbae), Ma Chi Xian 
(Herba Portulacae), Huang Lian (Rhizoma Coptidis), Huang Bai (Cortex Phellodendri), 
Cang Zhu (Rhizoma Atractylodis), Wu Bei Zi (Galla Chinensis), He Zi (Fructus 
Chebulae), Ku Fan (processed Alumen), Qing Dai (Indigo Naturalis), Shi Gao (Gypsum 
Fibrosum), Hua Shi (Talcum), Ku Shen (Radix Sophorae Flavescentis) and Lu Gan Shi 
(Calamina) were used in included studies.  These Chinese herbs were under the 
categories of “Heat-clearing”, “Damp-resolving”, “Damp-draining”, “Hemostatic”, 
“Astringent”, and “Externally applied and miscellaneous” in Chinese materia medica 
(Z. J. Li, 2008).  All included studies used different herbs in their treatment intervention 
except Huang Bai (Cortex Phellodendri) which was used in two included studies.   
In terms of control interventions, all included studies used conventional 
medicines.  For example, one study (Ma 2007) used calamine lotions, one study (Yang 
2007) used antihistamine and calcium and another study (Nie 2002) used varieties of 
controlled intervention including penicillin, corticosteroid creams and chlorpheniramine.   
Treatment durations ranged from three to 10 days in included studies. All studies 
reported follow-up data after the last treatment.  Follow-up periods were six and 12 
months respectively in two studies (Ma 2007; Yang 2007) and another one did not state 
when the follow-up was performed (Nie 2002). 
 
4.2.4 Types of Outcome Measures 
Two studies (Ma 2007 and Yang 2007) used percentage of treated patients with 
improvement of skin lesions and less itching with the terms of “recovery”, “significant 
improvement” and “effective” as their primary outcome measures.  One study (Nie 
2002) used percentage of treated patients with improvement of skin lesions with the 
terms of “significant improvement” and “effective” as its primary outcome measures.  
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None of the included studies used scoring system such as SCORAD, EASI or SASSAD 
for measuring the severity of the condition.  QoL was not assessed in any included 
studies.  Table  6 summarises the outcome measures in included studies. 
Table 6: Summary of Outcome Measures 
 
Outcome Study Number of 
Evaluation 
(N) in 
Treatment 
Group 
Number of 
Evaluation 
(N) in 
Controlled 
Group 
Number of 
Event (n) in 
Treatment 
Intervention  
Number of 
Event (n) in 
Controlled 
Intervention 
Statistic 
used and 
p Value 
Itching 
Relief 
Ma 
2007 
(N=68) 
38 30 36 20 t-test 
and Chi-
square 
test (χ 2 
= 7.565 
). 
 p < .05 
 Yang 
2007 
(N=75) 
40 35 37 23 Did not 
state. p 
< .01 
Itching 
Relief 
and 
Improve-
ment of 
Skin 
Lesions 
Ma 
2007 
(N=68) 
38 30 36 20 t-test 
and Chi-
square 
test (χ 2 
= 7.565 
). p < 
.05 
 Nie 
2002 
(N=309) 
160 149 160 89 Did not 
state. p 
< .01 
 Yang 
2007 
(N=75) 
40 35 37 23 Did not 
state. p 
< .01 
 
Note:  n = number of events  N = number of participants
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4.3 Description of Individual Studies 
 
4.3.1 Ma 2007 (Ma & Li, 2007) 
Ma’s study reported that 68 children with infantile eczema, aged from two to 24 
months were randomised into treatment group (N=38) and control group (N=30).  
Chinese herbal oil (Zi Cao You 紫草油) was used three to five times daily for seven 
days on the treatment group. Calamine lotion was used for comparison.  Both diagnosis 
and outcome measures were set by the clinicians who claimed a total effective rate of 
94.7% in intervention group (36/38) and 70% in control group (20/30) (p < .05).   
Incidentally, it was discovered that the final number used for analysis in the control 
group was actually 29 even though the initial claim was 30.  The authors stated that the 
efficacy of Zi Cao You was superior to that of calamine lotion for treatment of infantile 
eczema.   
 
4.3.2 Nie 2002 (Nie, 2002) 
Nie’s study provided CHM lotion (Formula was unnamed) to 160 patients who 
were diagnosed with childhood eczema and aged from two to 12 months in the 
intervention group.  The lotion was applied to the affected skin for 30 minutes once per 
day for three to five days.  Diagnosis and outcome measures were determined by the 
clinician who assessed symptoms and signs of patients.  Intramuscular injection of 
penicillin, topical usage of cortisone creams and oral intake of chlorpheniramine were 
used in control group with 149 cases. The author claimed that there was a 100% of the 
total effective rate in CHM lotion group (160/160) and 61.07% in control group 
(91/149).  Rate of relapse was measured with 42.50% in CHM lotion group (68/160) 
and 90.11% in control group (82/149).  The author claimed that there was statistical 
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significance between the two groups with respect to the total effective rate and relapse 
rate (p < .01).   
 
4.3.3 Yang 2007 (S. M. Yang, 2007) 
Yang’s study reported there were 40 children aged from one to 24 months with 
infantile eczema in the intervention group and there were 35 children with the same age 
range in control group. CHM power (formula was unnamed) was used externally three 
to four times per day for seven to 10 days.  Oral intakes of antihistamine and vitamin B 
complex, calcium tablets were used in control group.  Diagnosis and outcome measures 
were set by the clinician who claimed there was 92.50% total effective rate in 
intervention group and 65.71% in control group (p < .01).  The author concluded that 
efficacy of the CHM powder was significantly superior to that of antihistamine and 
vitamin B complex, calcium tablets for treatment of infantile eczema.   
 
4.4 Assessment of Risk of Bias on Included Studies 
Risk of bias in all three included studies were classified as “unclear” with the 
items which consist of the domains of randomisation, sequence generation, allocation 
concealment, blinding of participants, personnel and outcome assessors, and items of 
incomplete outcome data.  These were due to lack of relevant data on the published 
papers of those included studies.  The graph of the assessment is shown in Figure 4. 
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Figure 4: Risk of Bias Graph 
 
                  
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
  
 
 All authors claimed that their study was “randomised controlled clinical study”. 
However, none of them provided methods of randomisation and how the random 
number was allocated to the groups.  No included studies reported blinding when the 
studies were conducted.  There was a missing datum in Ma’s study (Ma & Li, 2007); 
the missing datum was not addressed by the author.  Letters for further information of 
randomisation method, allocation concealment, blinding, incomplete outcome data and 
statistic method were sent to the corresponding authors of the included studies but none 
of them replied.  There was insufficient information such as unreported findings to 
determine bias relating to the selective reporting.  The summary for risk of bias of the 
each included study is shown in Figure 5. 
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Figure 5:  Risk of Bias Summary 
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4.5 Treatment Effects of Topical Application of CHM for AE 
 
 
As the interventions of included studies used different categories of CHMs that 
are different in nature, and consequently producing different effects, it was, therefore, 
unlikely that these studies would all estimate the same treatment effect.  For this reason, 
we used RevMan 5 statistical method of Mantel-Haenszel with random-effects analysis 
model to pool data from included studies for estimate their overall effects. 
 
4.5.1 Percentage of Trial Participants with “Effective” Improvement in Skin Itching 
Relief 
Ma’s study (Ma & Li, 2007) and Yang’s study (S. M. Yang, 2007) reported skin 
itching relief as their outcome measures.  Ma’s study expressed the degree of itching 
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relief as “recovery”, “significant” and “effective” in both CHM and control groups.   
Yang’s study expressed as “significant” and “effective” in both CHM and control 
groups.  We combined the figures on “recovery”, “significant” and “effective” and 
expressed as “total effective rate of skin itching relief” and analysed the overall effect 
by comparing topical application of CHM with the controlled intervention 
(conventional medicines).  The forest plot of comparison showed that topical 
application of CHM significantly relieved skin itchiness (RR 1.41, 95% CI 1.18 to 
1.70); Z = 3.70 (p = .0002) compared with controlled intervention (Figure 6).  I² = 0%. 
 
Figure 6: Comparison of the Outcome of Total Effective Rate of Skin Itching Relief 
between Topical Application of CHM and Controlled Intervention 
 
Study or Subgroup
Ma 2007
Yang 2007
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 3.70 (P = 0.0002)
Events
36
37
73
Total
38
40
78
Events
20
23
43
Total
30
35
65
Weight
48.3%
51.7%
100.0%
M-H, Random, 95% CI
1.42 [1.09, 1.85]
1.41 [1.09, 1.82]
1.41 [1.18, 1.70]
CHM Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours control Favours CHM
 
Foot note: “Total effective rate of skin itching relief” is a sum of the skin itching relief rate 
expressed as “recovery”, “significant” and “effective” by the authors of the included studies.  
 
4.5.2 Percentage of Trial Participants with “Effective” Improvement of Skin Lesions 
Nie’s study (Nie, 2002) reported improvement of skin lesions as its outcome 
measure and expressed the improvement as “significant” and “effective” in both CHM 
and control groups.   Ma’s study (Ma & Li, 2007) and Yang’ study (S. M. Yang, 2007) 
reported skin itching relief as well as improvement of skin lesions as their outcome 
measures.  Ma’s study expressed the degree of itching relief and improvement of skin 
lesions as “recovery”, “significant” and “effective” in both CHM and control groups.  
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Yang’s study expressed as “significant” and “effective” in both CHM and control 
groups.  We combined the figures on “recovery”, “significant” and “effective” and 
expressed as “total effective rate of improvement of skin lesions” and analysed the 
overall effect by comparing topical application of CHM to controlled intervention. The 
forest plot of comparison showed that topical application of CHM significantly 
improved the skin lesions (RR 1.56, 95% CI 1.40 to 1.73); Z = 8.27 (p < .00001) 
compared to controlled interventions (Figure 7).  I² = 0%. 
 
Figure 7: Comparison of the Outcome of Total Effective Rate of Improvement of Skin 
Lesions between Topical Application of CHM and Controlled Interventions 
 
Study or Subgroup
Ma 2007
Nie 2002
Yang 2007
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.61, df = 2 (P = 0.45); I² = 0%
Test for overall effect: Z = 8.27 (P < 0.00001)
Events
36
160
37
233
Total
38
160
40
238
Events
20
91
23
134
Total
30
149
35
214
Weight
15.9%
67.2%
17.0%
100.0%
M-H, Random, 95% CI
1.42 [1.09, 1.85]
1.63 [1.44, 1.86]
1.41 [1.09, 1.82]
1.56 [1.40, 1.73]
CHM Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours control Favours CHM
 
 
4.5.3 Heterogeneity of Included Studies 
Dichotomous data (total effective rate of outcome measure) were tested by 
Mantel-Haenszel with random-effects analysis model and expressed as RR with 95% 
CI.  There was no heterogeneity identified among the included studies as I² was 0% 
across the three included studies. 
 
4.5.4 Reporting Bias 
Reporting bias was not assessed by method stated on Section 3.5.3 of Chapter 3 
as there were only three studies included in the meta-analysis. 
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4.5.5 Subgroup Analysis 
No subgroup analysis was performed as there was no heterogeneity across the 
included studies and participants in all included studies were children and application of 
intervention was not based on CM syndrome differentiation. 
 
4.5.6 Sensitivity Analysis 
No sensitivity analysis was tested as there was no heterogeneity across the 
studies for the outcome measures (I² statistic < 50%). 
 
4.5.7 Summary of Effects across the Included Studies 
We used the Grades of Recommendation, Assessment, Development and 
Evaluation (GRADE) system recommended by the Handbook to assess level of 
evidence on outcome measures. 
Table 6 lists the main outcome measures used by the included studies.  
Improvement of skin lesions was used as main outcome measure in all included studies. 
Two studies (Ma & Li, 2007; S. M. Yang, 2007) also measured skin itching in 
conjunction with improvement of skin lesions as outcome measure.  Neither score index 
for measurement of AE severity such as SCORAD, EASI, SASSAD nor score of QoL 
was employed as outcome measures in any of the included studies.   As mentioned on 
Section 4.3.1, the final number used in analysis was one less than that initially quoted in 
Ma’s study i.e. 30 becomes 29.  It is not clear if this missing datum was an oversight or 
dropout.  If it was due to dropout, then there was no attempt by the authors to conduct 
an ITT.   
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Table 6: Summary of Effects across the Included Studies 
 
Outcome Measures 
 
Statistic Method 
and p value  
Effect Size 
Risk Ratio 
[95% CI] 
Level of Evidence Study 
Treatment (n/N) Control (n/N)    
Ma 2007 1. Itching relief and rashes disappeared 
completely (recovery): 8/38 
2. Itching significantly relief and rashes 
disappeared > 60% (significant): 16/38 
3. Itching relief and rashes disappeared 
20%-30% (effective): 12/38 
4. No itching relief and rashes disappeared 
< 20% (ineffective): 2/38 
(1. + 2. + 3. = 36/38) 
1. Itching relief and rashes disappeared 
completely (recovery): 3/30. 
2. Itching significantly relief and rashes 
disappeared > 60% (significant): 11/30. 
3. Itching relief and rashes disappeared 
20%-30% (effective): 6/30. 
4. No itching relief and rashes disappeared 
< 20% (ineffective): 9/30. 
(One datum missed) 
(1. + 2. + 3. = 20/30)  
t-test and Chi-
square test (χ 2 = 
7.565 ). 
p < .05 
1.42 [1.09, 
1.85] 
Low, unclear risk of 
bias with serious 
limitations in the 
design and 
implementation ( 
lack of allocation 
concealment and 
blinding ) 
 
 
Nie 2002 1. Skin lesions disappeared with small 
scales (significant): 130/160 
2. Skin lesions improved (effective): 
30/160 
3. Skin lesions not improved (ineffective): 
0/160 
(1. + 2. = 160/160) 
1. Skin lesions disappeared with small 
scales (significant): 2/149 
2. Skin lesions improved (effective): 
89/149 
3. Skin lesions not improved (ineffective):  
58/149 
(1. + 2. = 91/149) 
Did not state 
statistic method. 
p < .01 
1.63 [1.44, 
1.86] 
Low, unclear risk of 
bias with serious 
limitations in the 
design and 
implementation ( 
lack of allocation 
concealment and 
blinding ) 
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Yang 
2007 
1. Itching relief completely and skin 
lesions disappeared completely within 7 
days (significant): 25/40 
2. Itching relief and skin lesions 
disappeared within 10 days (effective): 
12/40 
3. Itching and skin lesions not relief after 
10 days (ineffective): 3/40 
(1. + 2. = 37/40) 
1. Itching relief completely and skin lesions 
disappeared completely within 7 days 
(significant): 9/35 
2. Itching relief and skin lesions 
disappeared within 10 days (effective): 
14/35 
3. Itching and skin lesions not relief after 
10 days (ineffective): 12/35 
(1. + 2. = 23/35) 
 Did not state 
statistic method. 
p < .01 
1.41 [1.09, 
1.82] 
Low, unclear risk of 
bias with serious 
limitations in the 
design and 
implementation ( 
lack of allocation 
concealment and 
blinding ) 
 
 
 
Note: n = number of events N = number of participants 
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4.6 Adverse Events  
None of the included studies provided any information on adverse events in their 
studies.  Thus, meta-analysis could not be performed to evaluate the safety of topical 
application of CHM for AE. 
 
4.7 Studies with Multiple Treatment Groups and Unit of Analysis Issues 
None of the included studies have more than two intervention sites.  No study 
involved measurements on different body parts such as comparison of a site on one arm 
versus another site on the other arm.   
 
4.8 Discussion and Recommendations 
 
4.8.1 Summary of Results  
This is the first systematic review with stipulated methodological features for 
evaluation of effectiveness and safety of topical application of CHM for AE.  All three 
included studies used Chinese medicinal substances for treatment of infantile eczema or 
childhood eczema and made comparison of the outcome measures with various types of 
controlled interventions.  The included studies used clinician rated outcome such as skin 
lesions and patient self-rated outcome i.e. skin itching as primary outcome measures.  
Authors of the three included studies all claimed that there were statistical 
significant differences between the treatment group and control group, and effects of 
treatment interventions were always superior to what in the controlled interventions.   
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4.8.2 Strength of the Evidence  
All included studies had moderate sample size (N > 50) with a total of 452 
participants.  The included studies were designed as parallel controlled clinical studies 
where controlled interventions were used for comparison of measurement of 
effectiveness of the treatment interventions. 
   
4.8.3 Weakness of the Evidence 
All of the included studies were of low quality and associated with several major 
methodological weaknesses.  For example, although all included studies used 
randomisation for grouping of participants, none of them stated method of 
randomisation.  When we requested further information from the corresponding authors 
of the included studies, none of them responded.  Inadequate randomisation could give 
rise to an investigator’s bias for grouping of participants; consequently affecting the 
outcomes (J. P. Liu, 2006).  The absence of using validated outcome measure 
instruments such as the SCORAD, EASI or SASSAD in the included studies made 
quantifiable data analysis almost impossible (Eichenfield, et al., 2003).  In this review 
the three studies happened to use different diagnostic, inclusion and exclusion criteria as 
well as different herbal formulae.  Furthermore, there were “unclear risks of bias” with 
serious limitations in the design and implementation such as lack of allocation 
concealment, blinding, and quantitative assessment of outcome in the included studies; 
therefore, it is difficult to draw a conclusion if topical application of CHM was effective 
to relieve skin itching and improve skin lesion in infantile eczema or childhood eczema 
because of the above-mentioned weaknesses.   
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Even though all included studies claimed that there were statistical significant 
differences in the outcome measures on CHM treatment groups compared with those in 
the control groups; however, due to low level of evidence strength and risks of bias with 
serious limitations assessed by the GRADE system, these claims could not be taken for 
granted.  In addition, we doubted the claim of 100% effective rate on treatment group 
reported by Nie’s study (Nie, 2002).  Although no adverse events were reported in the 
three included studies, data were unavailable for evaluation of their safety.   
 
4.8.4 Applicability of the Evidence 
As pointed out above in Section 4.8.3, there were numerous deficiencies that 
contributed to the overall low qualities of the included studies, thus more RCTs with 
rigorous methodological designs are needed to confirm the efficacies or otherwise.   
 
4.8.5 Suggestions for Future Studies 
Topical administration of medicines has a few advantages over the oral 
application of medicines. These include protecting the skin directly by using cream or 
other vehicle, removing the medication from the affected area immediately in case of an 
adverse reaction happened, and is particularly user-friendly in paediatric practices (R. 
H. Yang, 2005).  Evidence of effectiveness and safety of CHM for AE needs to be 
confirmed by RCT; in this regard, we identified three clinical studies, which employed 
topical application of CHM, and met the pre-set inclusion criteria from 164 potential 
studies.  Among these three studies, two studies used one common Chinese herb, Huang 
Bai (Cortex Phellodendri).  Pharmacological investigations demonstrated that Huang 
Bai possesses anti-inflammatory effect (Shen, 2000) which may help to explain some of 
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its effectiveness in treating AE.  Such promising pharmacological properties need to be 
confirmed by RCT, the gold standard for evaluating therapeutic benefits of 
interventions.  Although the three reviewed articles showed promising results, however, 
due to the low level of evidence strength, this review did not provide convincing 
statistical support for efficacy of CHM used topically for AE or infantile eczema or 
childhood eczema. Therefore, well-designed, adequately powered, randomised 
controlled clinical trials are needed to evaluate the efficacy and safety of topical use of 
CHM for managing AE.  
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Chapter 5  Results II - Protocol for a Pilot RCT of Topical 
Application of CHM for AE 
 
 
This chapter reports development of a protocol for a pilot RCT of topical application 
of CHM for AE based on the methodological methods stated in Section II, Chapter 3.  
 
5.1 Information 
 
 
5.1.1 Recommendations from the Systematic Review 
Further to the discussion in Chapter 4, a properly designed double-blind RCT is 
recommended to evaluate the efficacy and safety of CHM for the treatment of AE through 
topical administration.  Thus a protocol for a pilot RCT was developed in this thesis. 
 
5.1.2 Description of Intervention used in the Trial 
In this trial, the investigators will evaluate the efficacy and safety of an existing 
Chinese herbal formula named Modified Qingdaisan by topical administration for treatment 
of AE in children and adults through a randomised double-blind placebo-controlled clinical 
trial.  Qingdaisan (Indigo Naturalis powder) has been used for skin conditions in children and 
adults for at least 27 years in CM practice (Y. R. Wang & Wang, 1979).  As stated on Section 
2.13.2 of Chapter 2, this formula is one of the routine topical CHM formulae for AE and 
infantile eczema.  The proposed treatment intervention name as modified Qingdaisan is 
composed of five ingredients,  which are listed along with their active chemical components 
(Shen, 2000; L. H. Zhao, 2005) in Table 7 below. 
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Table 7: Ingredients of Modified Qingdaisan 
 
Pharmaceutical 
Name 
Medicinal Name in 
Latinate Form  
 
Chinese 
Pin Yin 
Chinese 
Character 
Active Chemical 
Components 
Indigo Naturalis Baphicacanthus cusia Qing Dai 
青黛 
Indican, Indirubin 
Rhizoma Coptidis Coptis chinesnsis Huang 
Lian 
黄连 
Berberine, 
Coptisine, 
Worenine 
Gypsum Fibrosum Calcium sulfate Shi Gao 
石膏 
CaSO4⋅2H2O 
Cortex Moutan  Paeonia suffiuticosa Mu Dan Pi 
牡丹皮 
Paeonol, 
Paeonoside, 
Paeonolide, 
Paeoniflorin 
Rhizoma 
Anemarrhenae  
Anemarrhena 
asphodeloides 
Zhi Mu 
知母 
Mangiferin, 
Timosaponin 
Sarsasapongenin, 
Markogenin, 
Anemarans, 
 
The above medicinal substances are listed on the Therapeutic Goods Administration 
Approved Terminology for Medicines (TGA, 1999).  All of the substances are traditional 
Chinese herbs and have been used safely for hundreds of years.  None of them are listed on 
the “The List of Prohibited Chinese Medicine Herbs in Victoria” issued by the Drugs and 
Poisons Unit of the Department of Human Services of Victoria on 24 March 2006 
(http://cmrb.vic.gov.au/information/schedherbs.html#list, accessed on 31 July 2011) nor in 
the Standard for the Uniform Scheduling of Medicines and Poisons No 1 (the SUSMP 
1)(TGA, 2010).   No adverse reactions have been reported in other clinical studies in which 
the interventions contain these herbs (W. Z. Chen, 2003).  The five medicinal substances will 
be in the form of herbal extract granules provided by a Good Manufacturing Practice (GMP) 
licensed company with a concentration of five to one ratio (i.e. five grams of raw herbs 
equivalent to one gram of herbal granules).   This formula will be in a 5% of cream with 95% 
of Polyethylene glycol (PEG) 1000 and will be administered topically twice daily for eight 
weeks in the trial.  As stated on Section 2.1 of Chapter 2, AE is a chronic inflammatory 
superficial skin disease; most of the active chemical components from this proposed CHM 
intervention have anti-inflammatory action.  For instance, Mangiferin in Zhi Mu (Rhizoma 
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Anemarrhenae), Berberine in Huang Lian (Rhizoma Coptidis), Paeonol in Mu Dan Pi (Cortex 
Moutan),  Isdirubin and Indigo pure in Qing Dai (Indigo Naturalis), all have the action of 
suppression of allergy (Shen, 2000) and Calcium in Shi Gao (Gypsum Fibrosum) has the 
action of maintenance of the physiological function of the macrophage (Yin & Guo, 1994).  
 
5.1.3 Statement of Compliance 
Once the protocol is approved by the RMIT Human Research Ethics Committee 
(HREC), the trial will be registered on Clinical Trial Notification (CTN) at TGA and the 
Australian New Zealand Clinical Trials Registry (ANZCTR) at the NHMRC Clinical Trials 
Centre.  This trial will be conducted strictly in compliance with the protocol, the principles of 
Good Clinical Practice (GCP) and relevant requirements.   
 
5.2 Trial Objectives 
 
The primary objective of this pilot study will be evaluating whether the topical 
application of CHM can effectively reduce severity of symptoms and signs and improve the 
QoL in children and adults with AE.  It will also assess the safety of the topical application of 
CHM for AE.  The secondary objective of this trial is to determine an appropriate sample size 
and dosages for future large scale RCT studies. 
 
5.3 Trial Design 
 
 The pilot study will be a 14-week randomised double-blind placebo-controlled clinical 
trial to evaluate the efficacy and safety of topical application of a CHM cream for moderate to 
severe AE in children or adults.  The 14 weeks comprise of two weeks baseline, eight weeks 
treatment phase, and four weeks follow-up period.  Figure 8 illustrates the flowchart of the 
study. 
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Figure 8: Flowchart of the Trial 
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group (N=32) 
 
Placebo cream 
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(N=32) 
Recruit participants by 
advertisement or referrals 
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PPs complete and return forms 
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PPs will be invited for initial assessment if eligible 
Baseline period 
Pre-eligible PPs wait for two weeks for washout and eligible PPs 
are included if the 2nd baseline Objective SCORAD score is ≥ 15  
Objectiv SCORAD score > 15 
Randomised participants (N=64) 
Randomised to 
treatment 
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(N=32) 
CHM cream 
Treatment period  
(N=32) 
Possible early 
withdrew/dropout (N=?)  
Endpoint (Visit 5) 
 Week 11 of the trial 
Collect all instruments and 
other responses 
Follow-up (Visit 6 on Week 14) 
Participants return instruments by mail  
Complete CHM 
cream treatment  
Complete placebo 
cream treatment  
Possible early 
withdrew/dropout (N=?)  
Final data collection and analysis 
 
Visit 1 (Week 3), 2 (Week 
5), 3 (Week 7), 4 (Week 9) 
Participants receive 
intervention products and 
instruments and being 
assessed on each visit 
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5.4 Randomisation 
 
Block randomisation method will be employed with four participants a block, two 
participants will receive the real treatment and the other two will be treated with inert cream 
(the placebo).  Randomisation code will be calculated via Microsoft Excel in “Function and 
Rand”.  Stratified randomisation will be employed as per their age and those who are aged 
from 12 months to 16 years old will enter the children subgroup and those who are over 16 
year old will be in the adult subgroup.  
 
5.5 Blinding 
 
Neither participants nor investigators will know if the participant is receiving real 
treatment or placebo.  Randomised numbers will be generated by an independent statistician 
using Excel program. The numbers will be randomly assigned into real treatment group and 
placebo group, and sealed into individual opaque envelopes, which will be allocated by a 
central officer who is unaware of participants’ details.  Envelopes were sequentially numbered 
and opened only after participant’s IDs were written on the envelope.  In the initial visit after 
baseline period, each participant will be asked to pick one sealed envelope from the pack of 
all the envelopes.  The envelopes will be opened by a CHM dispenser, who could be a 
registered CHM practitioner or registered CHM dispenser. The CHM dispenser then hands 
over the container with CHM cream or inert cream (the containers are identical in appearance 
and labeled) to the participant and gives the participant an oral and written instruction 
(Appendix 3) of method of usage of the cream.  The CHM dispenser will record information 
including participant’s ID, sequential number of the container and randomisation code on a 
Record Sheet of Dispensary (Appendix 4) independently for future data analysis.  The code 
will not be broken to participants and personnel who are involved in data entry and data 
analysis.  
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5.6 Interventions 
 
 
5.6.1 Treatment Intervention 
 
 The CHM cream (treatment intervention) will be prepared by an appointed 
manufacturer with GMP certificate.  PEG 1000 will serve as vehicle for both the intervention 
and placebo groups.  Table 8 lists compositions of those Chinese medicinal extracts in each 
container filled with 50 grams of PEG 1000 cream. 
 
Table 8: Compositions of the Chinese Herbal Medicine Cream 
 
Pharmaceutical 
Name 
Botanical Name Chinese Pin 
Yin 
Chinese 
Characters 
Compositions (Per 
50 Grams of PEG 
1000 Cream) 
Indigo Naturalis Baphicacanthus Cusia Qing Dai 
青黛 
2 grams  
Rhizoma Coptidis Coptis Chinesnsis Huang Lian 
黄连 
1 gram  
Gypsum Fibrosum Calcium Sulfate Shi Gao 
石膏 
1 gram  
Cortex Moutan  Paeonia Suffiuticosa Mu Dan Pi 
牡丹皮 
1 gram  
Rhizoma 
Anemarrhenae  
Anemarrhena 
Asphodeloides 
Zhi Mu 
知母 
1 gram  
 
The cream will be packaged in a plastic container with a label including the following 
information: Clinical trial external use only, apply the cream on the affected skin twice daily, 
keep out of reach of children, expiry date, the manufacturer, batch number and brief 
information of the trial (Appendix 5). 
 
5.6.2 Control Intervention 
A placebo will be applied to the control group.  PEG 1000 will also serve as the 
vehicle in the placebo. The smell, colour and apparent package of placebo will be as close to 
the treatment interventional cream as possible. 
The treatment or placebo cream will be applied by the participant or guardian on the 
participant’s affected skin lesion twice daily for eight weeks.  During this trial after the 
baseline period, the participants will be asked to come back to the trial centre for assessment 
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fortnightly that is on day 15, day 29, day 43, day 57 and day 71.  Day 71 is also the endpoint 
of the usage of the intervention products (both the CHM creams and placebo).  Day 99 will be 
the last day of the four weeks of follow-up period and the trial will be concluded on Day 99.  
Application of the creams should be stopped when any adverse reaction is notified either by 
participant, guardian or investigator. 
 
5.7 Selection and Withdrawal of Participants 
 
 Participants will be recruited through advertisement (Appendix 6) via local papers, 
posters, internet, organisations and referrals from general practitioners (GPs) or 
dermatologists.  Contact details of the potential participants will be recorded during their 
initial enquires and expression of interest in the trial (Appendix 7).  A Plain Language 
Statement (PLS) with information of the trial including the purpose of the trial, about the 
intervention, potential adverse reaction and ethical issues will be given to potential 
participants (Appendix 8).  All potential participants or their guardians will be provided with 
Informed Consent Forms (Appendix 9 and 10) and General Information Questionnaires 
(Appendix 11).  Potential participants will be interviewed and evaluated with the criteria of 
inclusion and exclusion (Appendix 12) in order to select suitable participants for the trial 
(Screening period). 
   
5.7.1 Selection Criteria  
• Inclusion Criteria  
The U.K. Working Party’s diagnostic criteria will be adapted for inclusion in this trial 
(C. Charman, et al., 2003; H. C. Williams, et al., 1994). 
I. Diagnosis of the condition: 
a) History of skin pruritus in the last 12 months plus three or more of the 
any followings; 
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b) History of  flexural involvement; 
c) Visible flexural dermatitis;  
d) Onset under the age of two (not used for children under four years 
old);  
e) Age: 12 months or above;  
f) Personal history of atopy such as asthma, allergic rhinitis or hay fever; 
II. Severity of AE   
Baseline objective SCORAD score ≥ 15 (moderate to severe) in two 
baselines measurements in interval of two weeks; 
III. Completion of informed consent forms. 
• Exclusion Criteria  
a) Those who have used corticosteroids or any preparation of CHM or 
other herbs for treatment of AE orally in the past 30 days;  
b) Those whose skin condition has been diagnosed with scabies or 
allergic contact dermatitis or seborrheic dermatitis or psoriasis; 
c) Age: less than 12 months; 
d) Those who are currently pregnant; 
e) Those who have renal or liver dysfunction 
 
5.7.2 Withdrawals and Dropouts 
 Without providing reasons, participants are allowed to withdrawal at any time during 
the trial.  However, withdrawal (dropout) of participant will be followed up to investigate the 
time and reason of withdrawal (Appendix 13).  Principle of ITT with worst scenario will be 
used in the final data analysis for any withdrawn participant or missing data (D. Wang & 
Bakhai, 2006). 
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5.7.3 Discontinuers 
 Participant will be advised to discontinue the treatment if there is a product-related 
adverse event or if the participant was not compliant i.e. using corticosteroid orally during the 
treatment period. Using corticosteroid topically is allowed for those participants who have 
been using corticosteroid topically before participating the trial and whose skin conditions are 
worsen during the trial treatment period.  However, same drug and dosage of the drug should 
be recommended and medicinal record will be well documented.  All discontinuers will not be 
replaced by new participants.  Principle of ITT with worst scenario will be used in the final 
data analysis for any missing data from discontinuers. 
 
5.8 Sample Size 
 
There is lack of statistic evidence for topical application of CHM for AE in RCTs with 
high quality.  This proposed trial is to test the efficacy of an intervention. Our hypothesis will, 
therefore, be that there is difference in the proportion of improvement between the 
intervention and control groups.  Calculation of the participant numbers is based on the 
following formula (Bulpitt, 1983): 
 
Formula   N = K [P1 (1- P1) + P2 (1- P2)] 
                             (P1-P2) ² 
 Set N be the minimum number for each of the two groups. 
 Set P1 be the proportion of the outcomes on the control group.  The proportion is 
estimated as 20%.  This estimation is based on the fact that the vehicle on the control group is 
made of PEG 1000, and there is no evidence PEG 1000 could improve the conditions in AE 
patients.  Thus the P1 in sample size calculation formula is 0.20. 
 Set P2 be the proportion of the outcomes on the herbal intervention group.  Since there 
are no previous publications of RCTs with similar herbal cream, for the purpose of this trial a 
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60% effectiveness is set as satisfactory target which is sufficient to distinguish significant 
difference between control and intervention.  The intervention group will be [(60%) – (20%)] 
= 40% improvement at the end point, then P2 is 0.40. 
 Set K be the square of the standardised normal deviate for type III error or r (r 
assumes the final better treatment is actually the worse treatment, in this proposed trial the 
type III error or r is very small).  If r is set at 5%, then K = 1.64² = 2.7.   
 
N = 2.7 [0.20 (1- 0.20) + 0.40 (1- 0.40)]   
             (0.20 – 0.40) ² 
 
Thus, N = 27.   
 Set estimated dropout rate is 20%, then N = 27 x 0.20 + 27 ≈ 32 
 There will be 32 participants for treatment intervention and placebo control group 
respectively with a total of 64 participants to be included based on the above calculation.  For 
future trials, more accurate sample size will be re-calculated based on the results of actual 
proportion of outcomes obtained from this pilot study. 
 
5.9 Baseline and Treatment Periods 
 
  When pre-eligible participants are selected, there will be 14 days of washout period.  
At the beginning of this period, SCORAD will be measured, and at the end of 14 days, they 
will be re-measured if the initial objective SCORAD score is 15 or greater.  The baseline 
period will also be considered as the screening period as only those participants who have 15 
or more objective SCORAD score in two weeks interval might go into the treatment periods.  
In order to test a hypothesis that the CHM cream is effective for treatment of AE regardless 
the different subcategories classified under the CM differentiation of syndrome, participants 
will be given a Chinese Medicine Syndrome Identification for AE instrument (Appendix 14) 
and assessed by a registered CHM practitioner for CM differentiation of syndrome at the 
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screening  stage.  A folder with Case Report Forms (Appendix 15) will be set up for each 
participant. 
 Treatment periods: Apply the intervention products twice daily for eight weeks. 
 Endpoint: on Day 71 (week 11) of the application of the intervention products or when 
an adverse reaction has been reported and nature of the adverse reaction has been evaluated 
by the investigator. 
 
5.10 Outcome Measures 
 
 
5.10.1 Measurements of SCORAD and QoL Index 
Efficacy of the treatment intervention and placebo will be evaluated via the changes of 
severity of the condition which will be measured by using the SCORAD including its 
subjective and objective items (Stalder & Taieb, 1993) (Appendix 16 and 17).  QoL index 
score such as the IDQOL (M.S. Lewis-Jones, et al., 2001) for children under four years old 
(Appendix 18);  the CDLQI for children from age five to 16 (M. S. Lewis-Jones & Finlay, 
1995) (Appendix 19) and the DLQI (Finlay & Khan, 1994) for adults (Appendix 20) will also 
be measured.  Permissions of using these instruments of QoL assessment for the trial have 
been provided by the authors. 
 
5.10.2 Primary and Secondary Outcome Measures 
 Changes in the subjective items, which will be expressed as VAS score and the 
objective items of the SCORAD score at the end of the treatment will be used as primary 
outcome measures.  Changes of the QoL index score at the end of the treatment will be used 
as secondary outcome measures.  The baseline measure for the SCORAD score and QoL 
index score will be set on the initial record at the screening period.  Both the SCORAD score 
and QoL index score will be measured at the endpoint.  The QoL index score will be recorded 
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at the screening period and at the end of the treatment period respectively.  A Daily Medical 
Record Sheet will be given to the participants or their guardians to record the details of 
administration of the intervention products and self rated symptoms and signs.  This daily 
record will also record the usage of any other forms of medications with their names and 
dosage (Appendix 21).  Participants or guardian’s self-rated symptoms (itchiness) and signs 
(redness, dryness or thickness of the skin) recorded in the Daily Medical Record Sheets, and 
the VAS Sheets will be used as primary outcome measures.    
 Outcome measures will be assessed and recorded on an Outcome Measures Sheet 
(Appendix 22) at each appointed time when the participants visit the trial centre.  The 
intervention products will not be given any more at the fifth visit on Day 71 of the trial and 
participants will be advised to stop using the intervention products one day before Day 71 of 
the trial (endpoint). 
 
5.10.3 Assessment of Safety 
 Safety of the intervention products will be monitored by way of any adverse reactions 
observed by the participants and their guardians or the trial investigator.  Blood sample of 
participants will be collected by an appointed registered nurse at the screening period and at 
the fifth visit of the trial for full blood test, IgE level, liver and renal function tests (Appendix 
23).  Blood tests will be authorised by an appointed medical officer and conducted in RMIT 
clinical trial centre. 
 Once receiving an adverse event report, participant will be advised to discontinue the 
usage of the intervention products and the trial investigator will examine the participant 
immediately.  Details of the adverse event will be recorded on Adverse Event Questionnaires 
(Appendix 24) and medical advice from the medical officer will be given to any case with 
serious adverse reaction.  
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In case of any adverse events or reactions, the investigator will manage such events or 
reactions in compliance with the guidelines of “Note for Guidance on Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting (CPMP/ICH/377/95)” 
issued by TGA (TGA, 2000).  A serious adverse event will be reported within 72 hours and 
adverse event will be reported within 15 days. 
 
5.10.4 Assessment of Participant Compliance 
 Participant compliance will be monitored each time when participants revisit the trial 
centre (Appendix 25).  Four weeks after the end of treatment period, participants will be 
followed up for further outcome measurements.  Table 9 summaries the schedule of the trial 
and provide a summary list for primary and secondary outcome measures. 
 80 
Table 9: Schedule of the Trial 
 
Items Title of the Documents Screening 
Period 
Baseline and 
Washout Period 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 
(Endpoint) 
Visit 6 
(Follow-
up) 
   Day 1 to 14 
Week 1 and 2 
Day 15 
Week 3 
Day 29 
Week 5 
Day 43 
Week 7 
Day 57 
Week 9 
Day 71 
Week 11 
Day 99 
Week 14 
Demographic 
information taking 
1. Record Sheet for 
Potential Participants  
2. Participant Information 
Sheet 
+        
Informed consent 
forms 
1. Prescribed Consent Form 
for Persons Participating in 
Research Projects 
Involving Interviews, 
Questionnaires or 
Disclosure of Personal 
Information 
2. Prescribed Consent Form 
For Persons Participating In 
Research Projects 
Involving Tests and/or 
Medical Procedures 
+        
General medical 
history taking 
1. General Information 
Questionnaires 
2. Inclusion/Exclusion 
Criteria 
+        
CM syndrome 
identification 
Chinese Medicine 
Syndrome Identification for 
AE 
 +       
Blood tests Pathology Tests +      +  
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Items Title of the Documents Screening 
Period 
Baseline and 
Washout Period 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 
(Endpoint) 
Visit 6 
(Follow-
up) 
Objective 
SCORAD 
Assessment Form for 
Objective Score of 
SCORAD 
+  + + + + + + 
Subjective 
SCORAD 
VAS for Assessment of 
Severity of AE 
+  + + + + + + 
QoL score 1. IDQOL 
2. CDLQI 
3. DLQI 
+  + + + + + + 
Distributions of 
treatment or 
placebo 
intervention cream  
Record Sheet of Dispensary   + + + +   
Daily medical 
record  
Daily Medical Record 
Sheet 
 + + + + + +  
Monitor of adverse 
event 
Adverse Event 
Questionnaires 
   + + + + + 
Compliance check 1.Record Sheet of 
Treatment 
2. Record Sheet of 
Withdrawal/Dropout of the 
Participants 
   + + + + + 
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5.11 Statistics 
 
Data will be analysed by using Statistical Package for the Social Services 
version 16.0 by an independent statistician.  Comparison of continuous variables (i.e. 
SCORAD scores) between baseline and endpoint within the intervention group, and 
between the intervention and placebo groups will be expressed as MD with 95% CI.  
Wilcoxon test will be performed for comparison of dichotomised data (i.e. 
“improved”) and will be expressed as RR with 95% CI.  All comparisons will be 
made in two-tailed and p-values < .05 is considered to be statistically significant.  ITT 
analysis will be performed on missing data as stated on Section 5.7.2.  Interim 
analysis and earlier stopping of the trial will be activated once a general serious 
adverse reaction that may potentially affect the safety of all participants is reported.   
 
5.12 Data Identification and Confidentiality 
 
The participant’s name, gender, date of birth, medical history and contact 
details will be collected.  Participants’ Information will be retained for 15 years, and 
will be disposed under the guidelines of “NHMRC (Joint National Health and 
Medical Research Council) / AVCC (Australian Vice-Chancellor’s Committee) 
Statement and Guidelines on Research Practice” (NHMRC, 1997).  Data will be kept 
in a locked file cabinet in the RMIT Trial Laboratory.  Only the investigator and his 
supervisors have access to the data.  However, the investigator will permit trial-related 
monitoring by authorities, review by RMIT HREC, and regulatory inspection, 
providing direct access to source data/documents for such monitoring, review or 
inspection. 
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5.13 Quality Control and Quality Assurance 
 
The intervention products (the CHM cream and placebo) will be manufactured 
by a GMP licensed company according to the standards set by TGA for therapeutic 
goods for listed medicines.  This includes the identification of raw materials and limit 
tests of heavy metals and contaminations.  In addition, the fingerprint profiles of 
methanol extracts of the products against reference standards (active chemical 
components identified from individual herbs) will be established using a Shimadzu 
HPLC (high performance liquid chromatography) system (model SCL-10Avp HPLC-
DAD) combined with a SPD-M10Acp diode array detector, reserve-phase C18 
column and gradient elution method.  The methanol extract will be prepared using an 
accelerated solvent extractor ASE 100 (Dionex, USA) under an optimised extraction 
protocol.  A single batch of products will be used for the clinical trial and chemical 
analysis.  A sample of products will be deposited at the RMIT herbal identification 
and analysis laboratory, WHO Collaborating Centre for Traditional Medicine at 
RMIT University.  The extraction and HPLC analysis will be carried out at RMIT 
University.  
 
5.14 Trial Investigators and other General Information 
The trial investigation team members will come from different academic 
backgrounds.  The trial investigators, who are in charge of history taking, input of 
inclusion/extrusion criteria questionnaires forms, CM syndrome identification forms 
will be CM practitioners with at least 10 years clinical experience and must be 
registered in the Division of Chinese herbal medicine with Chinese Medicine 
Registration Board of Victoria, Australia.  One of the team members will be an expert 
in herbal pharmacology and one member will be a statistician.  A western medicine 
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and Chinese medicine dermatologist will be appointed for providing expert advice.  
The trial will be sponsored by Traditional & Complementary Medicine Research 
Program, RMIT Health Innovations Research Institute and Discipline of Chinese 
Medicine, School of Health Sciences, RMIT University and authorised by the Head of 
Discipline and supervisors of the trial.  Sponsor’s medical expert (or officer) will be 
appointed once the protocol is approved.  The trial will be conducted at the Clinical 
Trial Laboratory, Building 202, Discipline of Chinese Medicine, School of Health 
Sciences, RMIT University, Plenty Road, Bundoora Vic. 3083 Australia.  
  
5.15 Ethics Issues 
 
The investigator will submit an application to RMIT HREC for approval prior 
to conduction of the trial.  The application will encompass all the relevant ethical 
issues such as risk and benefits of the trial, informed consent, protection of children 
and confidentiality. 
 
5.16 Publication Policy 
 
Manuscript of the trial report will be submitted to a professional journal for 
publication once the trial is concluded.  None of the information related to the privacy 
of the participants such as their names or contact details will be released in any 
publication. 
 
5.17 Financing and Insurance 
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The sponsor of this trial will arrange financial support for conduction of the 
trial.  The RMIT University will be responsible for public and products liability 
insurance covering legal liability of the insured to pay damages or compensation in 
respect of personal injury or damage to property as a result of an occurrence 
happening in connection with the trial. 
 
5.18 Comments 
 
This protocol outlines the necessity and feasibility for assessing the efficacy 
and safety of topical application of CHM cream (Modified Qingdaisan) for AE in the 
form of RCT with a small sample size. A randomised double-blind, placebo-
controlled parallel groups clinical trial has been well accepted by research profession 
as a gold standard method for evaluation of effectives and safety of an intervention 
(Kane, 2004; Vincent & Furnham, 1997).  The primary endpoints will be set on day 
71 after the applications of the last dose of intervention products.  The trial will be 
concluded on week 14 of the follow-up period following cessation of application of 
the intervention creams.  In the absence of reliable published RCT information, we 
proposed to set the endpoint of the trial on Day 71.  It is anticipated that results of this 
pilot study will provide more precise information in deciding outcome measurement 
time for the endpoint, and appropriate dosage for a larger scale of trial in future. 
Recruitment of participants is restricted to the age of 12 months and above to 
fulfil the diagnostic criteria set by the U. K. Working group.  We did not choose the 
commonly quoted Hanifin’s diagnostic guidelines for the diagnosis of AE because its 
minor criteria require an ophthalmologist to determine the condition. This is beyond 
our research resources at this stage. Objective score of SCORAD will be used at 
screening period for determination of severity of the condition.  Only those potential 
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participants who are assessed with moderate to severe AE for which the objective 
score of SCORAD is 15 or greater in the interval of two weeks will be included.  
Therefore, we design a 14-day washout period.  At the end of the washout period, the 
objective score of SCORAD will be measured again. These scores will be used as 
baseline measures. The objective score of SCORAD will also be used as one of the 
primary outcome measures and changes of QoL index will be used as secondary 
outcome measure.  Three sets of QoL questionnaires including IDQOL for 
participants under four years old, CDLQI for five to 16 years old and DLQI for 17 
year above will be employed.  These three sets of questionnaires for different age 
groups were developed by the same group of authors from Department of 
Dermatology Cardiff University, UK and they were designed to be assessing the same 
parameters using identical quantitative scales while being specific to different age 
groups, such that results are comparable across all three scales.   
This protocol is compiled based on the Checklist Item 4 for Reporting 
Randomised, Controlled Trials of Herbal Medicine Interventions recommended by 
the CONSORT Group (Gagnier, et al., 2006).  Item 4 includes 4A: Herbal medicinal 
product name, 4B: Characteristics of the herbal product, 4C: Dosage regimen and 
quantitative description, 4D: Qualitative testing, 4E: Placebo/control group and 4F: 
Practitioner.  All key issues on the Item 4 have been elaborated in this protocol.  For 
instance, the 4D: Qualitative testing of the intervention products is addressed in 
Section 5.13. 
The ultimate purpose of this pilot trial is to test the efficacy and safety of a 
designed CHM cream.  Further evaluation of the pharmacological action of the CHM 
cream could be conducted once the potential clinical efficacy is proved by this trial. 
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The protocol also details the process of the trial and states that the GCP rulings 
and other guidelines and regulations will be complied.  A set of forms including 
“Plain Language Statement”, “Informed Consents Forms” and “Case Report Forms” 
are ready for submission for ethics approval by RMIT HREC. 
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Chapter 6  General Discussion and Conclusion 
 
 
There are two main components in this thesis.  The first one aims at the 
collection of evidence to assess the efficacy and safety of topical application of CHM 
for AE by using methodology of Cochrane systematic review.  The second component 
focuses on designing a protocol for a pilot RCT of topical application of CHM for AE.    
AE is a common skin disorder in adults as well as in children especially in 
those aged six to seven years.  The prevalence of AE has increased over the last 10 
years in worldwide.  It is suggested that effective treatment of childhood eczema may 
prevent the persistence and development of asthma.  A consensus of diagnostic 
criteria and assessment of severity of AE has been well established and validated in 
conventional (western) medicine, but the standard first-line therapies in conventional 
medicine for management of AE are not satisfactory.  CHM has been used for 
treatment of AE for years although its efficacy has not been tested with scientific 
methodology.  At present there have been many RCTs evaluating efficacy of oral 
administration of CHM for AE. Their efficacies have also been reviewed and 
evaluated through the systematic review published by Cochrane Collaboration.  
However, there is distinct paucity of information regarding the topical usage of CHM 
for AE.  The systematic review in this thesis is the first one in CHM topical 
administration for AE, and it has led to the conclusion that existing evidence is far 
from convincing.  Therefore, there is a need to evaluate the efficacy and safety of 
topical application of CHM for AE by using the methodology of Evidence-based 
medicine (EBM).   
EBM is defined as “the conscientious, explicit, and judicious use of current 
best evidence in making decisions about the care of individual patients” (Sackett, 
 89 
Rosenberg, Gray, Haynes, & Richardson, 1996).  The practice of EBM indicates 
integration of clinician expertise with the best available external clinical evidence 
which is gained from systematic research.  EBM provides scientific standards of 
evidence for clinical practices where the efficacy of those practices is measurable.  
Decision marking of applying the most effective techniques or interventions in 
clinical practices no longer relies on clinician’s accumulated personal experiences, but 
the scientific evidence that obtained by other researchers (Timmermans & Mauck, 
2005).  The strength of evidence in EBM is composed of level of evidence, quality 
and statistical precision of study design.  Level of evidence ranks from the top “I 
degree”, in which evidence is obtained from a systematic review of all relevant RCTs 
to the bottom “IV degree” where evidence is collected from case series study 
(NHMRC, 2000).  The practice of EBM gives rise to an opportunity for devolvement 
of traditional Chinese medicine in contemporary context (J. P. Liu, 2006).  It is fair to 
suggest that for CM to be better respected and recognised by the mainstream 
healthcare system, its practice in terms of effectiveness should be scientifically 
supported by EBM.  Researches of efficacies of CHM by way of EBM approaches 
such as conducting well designed RCTs that follow the generally accepted gold 
standards, and systematic reviews of such RCTs as well as laboratory analytical 
confirmations of the pharmacological properties of Chinese herbs all help to further 
extend the boundary and theories of, and also promote confidence in traditional 
Chinese medicine.  The systematic review in this thesis is a small contribution to this 
EBM development of contemporary CM paradigms, and such rapidly burgeoning 
evidences not only serve to provide more convincing supports to the unique CM 
practice of syndrome differentiation and treatment principles, but also assist clinicians 
to treat patients optimally and confidently.   
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A protocol for a pilot RCT for the purpose of evaluating the efficacy and 
safety of a CHM cream for AE administrated topically has been developed in this 
thesis.  The trial has been designed to avoid any potential risks of bias in its final 
outcome measures.  Such potential risks of bias are randomisation, sequence 
generation, allocation concealment, blinding of participants, personnel and outcome 
assessors and items of incomplete outcome data.  The global score system will be 
employed for primary outcome measures and changes of QoL index as secondary 
outcome measure.  Quality control and assurance of the intervention products has also 
been addressed to assure the consistent final outcomes of the trial.  The RCT will be 
conducted in compliance with the required ethical standards.  
In sum, the systematic review and detailed analysis of the three included 
studies led to the conclusion of low level of evidence strength.  Thus, they did not 
provide convincing evidential support for effectives of CHM used topically for AE or 
infantile eczema.  Therefore, there is a need to evaluate the efficacy and safety of 
topical application of a CHM formula to treat AE through a well designed randomised 
double-blind placebo-controlled trial.  The trial will be conducted as soon as the 
protocol is approved by the RMIT HREC. 
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Appendix 1 Data Extraction Form∗ 
 
(For systematic review of topical application of Chinese herbal medicine for atopic 
eczema) created by Sherman Gu and commended by Dr Angela Yang on 22 April 
2008) 
 
 
1. Study ID: 
 
 
2. Study Design: 
 
2.1 Design: parallel group   cross over   other (describe) 
 
2.2 Randomization 
Was the study described randomised?    Yes / No / Unclear 
         
Evidence: 
Comments: 
 
2.2.1 Sequence generation:  
Was the allocation sequence adequately generated?       Yes / No / Unclear 
         
Evidence: 
Comments: 
 
2.2.2 Allocation concealment: 
Was allocation adequately concealed?   Yes / No / Unclear 
         
Evidence: 
Comments: 
 
2.2.3 Blinding 
Was knowledge of allocated interventions adequately prevented during the study? 
        Yes / No / Unclear 
         
Evidence: 
Comments: 
 
2.2.4 Incomplete outcome data 
Were incomplete outcome data adequately addressed? Yes / No / Unclear 
         
Evidence: 
Comments: 
 
                                                 
∗The form was adapted and modified from the Data Extraction Form recommended by the Cochrane 
Skin Group.  
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2.2.5 Selective outcome report 
Are reports of the study free of suggestion of selective outcome reporting? 
        Yes / No / Unclear 
Evidence: 
Comments: 
 
2.2.6 Topic-specific, design-specific or other potential threats to validity 
Was the study apparently free of other problems that could put it at a risk of bias? 
        Yes / No / Unclear 
Evidence: 
Comments: 
 
 
 
3 Participants 
 
3.1 Setting:  inpatient / outpatient/ others (describe) 
 
3.2 What are the criteria for patients to join the trial? (describe) 
 
3.3 Age?  
 
3.4 Diagnosis 
 
3.5 Duration of symptoms? 
 
3.6 Other? 
 
Number of patients 
randomised 
Intervention 1 Intervention 2 Total 
Age range: 
Mean age (SD) 
   
Gender 
No. male 
No. female 
   
Total number of patients    
    
  
4 Withdrawals and dropouts 
 
4.1 ‘Intention to treat’ analysis:     Yes / Not stated / No 
 
 Intervention 1 Intervention 2 Total 
Number of withdrawals    
Reason for withdrawal    
Number lost to follow 
up 
   
Final number of 
patients evaluable 
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4.2 Summary:  Minimal missing outcome data / ITT unclear? / Substantial 
missing outcome data 
 
5 Description of interventions 
 
Intervention 1 
Formula 
 
Ingredients and dosage 
 
Route of administration 
 
Duration of treatment 
 
Follow-up 
 
Other 
 
Intervention 2 
Formula 
 
Ingredients and dosage 
 
Route of administration 
 
Duration of treatment 
 
Follow-up 
 
Other 
 
 
6 Outcomes 
 
All data are number of patients, not percentages 
 
 Intervention 1 Intervention 2 
 Baseline End point Baseline End point 
Global 
improvement 
(measured by)  
    
Itching relief 
(measured by) 
    
Time to 
remedication 
(measured by) 
    
Other 
(measured by) 
    
Adverse effects 
Major 
(withdrawal 
from study) 
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Adverse effects 
Minor  
  
Assessment of compliance undertaken?   Yes/ not stated / no 
 
 
7 Comments 
 
Date form completed: 
 
 
Form completed by: 
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Appendix 2  Template of Letter to Corresponding Author 
for Further Information 
 
(English version) 
 
13th May 2008: 
Attention: 
 
From: 
Mr. Sherman Gu 
285 Stud Road, Wantirna South Vic 3152 Australia 
Email: sherman.gu@rmit.edu.au 
 
Phone + 613 9925 7635 
 
 
Dear_____________________ (insert name of the corresponding author here) 
 
 
Re: Further Information about Your Study 
 
 
I am writing this letter in regard with request further information about your 
paper published on ___________________(insert Journal here)  
______________(insert title of the paper)____________             (insert volume, page 
and year of publication) . 
 
I am currently conducting a systematic review as part of my research program 
at the School of Health Sciences, RMIT University, Australia. 
 
Your paper has met the inclusion criteria.  It is assumed that your data might 
not be published in full due to word limitation of publication, and those unpublished 
data are important for my research.  Therefore, I wonder if you could provide more 
information about your study. 
 
1. Was your study a randomised controlled study?  If yes, please provide 
information about the method of randomisation, sequence generation and allocation 
concealment; 
2. Did your study involve blinding?  If yes, double or single blind? Please 
provide information of Blinding of participants, personnel and outcome assessors; 
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3. Did your study have any incomplete data?  Please provide any reason if there 
was any incompletion of treatment.  Did you follow up for the uncompleted patient? 
Did you perform intention-to-treat (ITT) analysis? 
4. Details of the statistical methods and data of your study. 
 
Information you provide will be essential for me to get an accurate conclusion 
of this research program and further enrich the knowledge of Chinese medicine in 
atopic eczema. 
 
I look forward to hear from you soon. 
 
Yours truly, 
 
 
 
Sherman Gu 
 
Encl: (copy of the published paper) 
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RMIT 
UNIVERSITY 
 
 
Traditional & Complementary Medicine Research Group, School of Health Sciences 
 
Appendix 3 Instruction of Usage of the Cream 
 
1. Please clean the affected skin with warm clean water, then dry the skin 
with clean towel before apply the cream on; 
2. Open up the sealed container and apply the cream evenly on the affected 
areas of the skin twice daily (morning and evening); 
3. Close the container and store it in a refrigerator; 
4. If you feel any adverse reaction after using the cream, please stop using it 
and call up the trial investigator on (03) 9925 7635 immediately.  
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Appendix 4 Record Sheet of Dispensary 
 
Participant’s 
ID Number 
Sequential 
Number of the 
Container 
Randomisation 
Code 
Date of 
Dispensary 
Dispenser’s 
Signature 
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Appendix 5 Template of Label on the Container  
 
For clinical trial externally use only   Keep out of reach of children 
 
Trial approval code:      
Manufacturer: 
Sponsor: Prof. Charlie Xue   Principal investigator: Sherman Gu 
Site: Clinical Trial Laboratory, Building 202, Discipline of Chinese Medicine, 
School of Health Sciences, RMIT University, Plenty Rd., Bundoora Vic 3083  
Quantity: 50 ml    Sequential No.     
Instruction:  Apply the cream evenly on affected areas twice daily.  
   
Batch No.     Expiry date: 
 
Participant’s initial:    Participant’s ID: 
___________________________________________________________________ 
Keep the cream refrigerated when not in use. 
Please return the container and any unused cream to investigator at your next visit. 
Contact phone number for the trial: Sherman Gu: (03) 9925 7635 
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UNIVERSITY 
 
Traditional & Complementary Medicine Research Group, School of Health Sciences 
Appendix 6 Media Advertisements for Recruitment of 
Participants 
 
 Eczema Sufferers Wanted  
 
Are you or your kid suffering from eczema or dermatitis?  Do you concern 
about the side effects of steroid drugs?  If you or your kid are 1 year old or above, and 
have been diagnosed as eczema, or atopic eczema or atopic dermatitis by a GP or 
dermatologist, you might be eligible to participate in this clinical trial which involves 
using traditional Chinese herbal preparation topically for 8 weeks. 
The trial has been approved by the appropriate authorities and your personal 
information will be absolutely confidential.    
For more information or to register the trial, please contact A/Prof Chunguang 
Li on (03) 9925 7635 or email sherman.gu@rmit.edu.au 
Mr. Gu is a registered Chinese medicine practitioner in both divisions of 
Chinese herbal medicine and acupuncture at Chinese Medicine Registration Board of 
Victoria. 
 
The clinical trial will be conducted at the following venue: 
Clinical Trial Laboratory,  
Discipline of Chinese Medicine, School of Health Sciences 
Building 202, Level 4, Room 46,  
RMIT University Bundoora West campus, Plenty Road.  Bundoora Vic. 3083 
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Appendix 7 Record Sheet for Potential Participants  
 
Number Participant 
and/or 
Guardian’ 
Surname 
Given Name Gender 
 
Postal Address Date 
of 
Birth 
Tel: Home Tel: Business Mobile: Email 
Address 
PLS* 
And 
GIQ** 
Forms 
Sent out 
Initials 
and 
Signature 
of the 
Recorder  
1            
2            
3            
4            
5            
6            
7            
8            
9            
10            
 
*PLS: Plain Language Statement (Participant Information Sheet) 
 
** GIQ: General Information Questionnaires 
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Appendix 8  Participant Information Sheet  
(Plain Language Statement)* 
Date: ____________ 
 
Dear _________________ 
You are invited to participate in a research project being conducted by 
Traditional & Complementary Medicine Research Program, RMIT Health 
Innovations Research Institute, & Discipline of Chinese Medicine, School of Health 
Sciences, RMIT University.  This information sheet describes the project in 
straightforward language, or ‘plain English’.  Please read this sheet carefully and be 
confident that you understand its contents before deciding whether to participate. If 
you have any questions about the project, please ask one of the investigators listed 
below.  
 
1. Name of the Trial:  
Pilot Randomised Double-Blind Placebo-Controlled Clinical Trial of Topical 
Application of Chinese Herbal Medicine for Atopic Eczema 
2. Investigators of the Trial: 
 
Mr. Sherman Gu (Chinese Medicine Master Degree Student) 
 
A/Prof. Chun Guang Li (Senior project supervisor: Principal research fellow, 
Chinese Medicine Research Group, chunguang.li@rmit.edu.au, 9925 7635) 
 
Dr. Angela Wei Hong Yang (Project supervisor: Lecturer, Discipline of 
Chinese Medicine, anegla.yang@rmit.edu.au, 9925 7175) 
 
Prof. Charlie Xue (Project consultant: Head, Discipline of Chinese Medicine, 
charlie.xue@rmit.edu.au, 9925 7745) 
 
                                                 
*
 The information sheet was adapted and modified from “Plain language statements and obtaining 
informed consent of participants – guidelines” RMIT 2004, Document ID r8chsu4o7t2iz. 
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3. Purpose of the Trial 
The Chinese herbal medicine (CHM) cream is an exited external use 
traditional Chinese herbal preparation for treatment of skin disorders such as 
eczema or atopic eczema for years.  The formula has shown it is effective and 
safe clinically.  There has no side effect or adverse reaction observed so far at 
the doses that will be tested in this trial.  The purpose of this trial is to evaluate 
the efficacy and safety of this herbal preparation in treatment of atopic eczema 
with strictly methodological method. 
 
This trial has been approved by the RMIT Human Research Ethic Committee.  
Mr. Sherman Gu, the chief investigator of the trial, is a registered Chinese 
medicine practitioner in both divisions of Chinese herbal medicine and 
acupuncture in the Chinese Medicine Registration Board of Victoria.  Mr. Gu 
was also a clinician in RMIT Complementary Medicine Teaching Clinic from 
1999 to 2005.  The trial is part of a Master’s degree of Applied Science 
(Chinese Medicine) supervised by A/Prof. Chun Guang Li, Dr. Angela Yang 
and Prof. Charlie Xue is the consultant to monitor and review the progress of 
the project. 
 
4. Procedures of the Trial 
You have been referred by your health care provider or invited through media 
advertisement from our project team.  It is expected that a total of 64 
participants will be recruited. In this trial, you will be interviewed in the trial 
center and fill out some forms which will record your present skin condition 
and other information.  You might be asked questions, for instance, “Over the 
last week, how itchy, sore, painful or stinging has your skin been?”  The 
forms will be used at the end of the trial to compare the different of your 
conditions with the previous information you provided. 
 
The trial is a double-blind trial for atopic eczema, lasting only 14 weeks.  The 
trial will compare a Chinese herbal medicine cream with a placebo (dummy).  
This means that both you and Mr. Gu will not know whether the cream that 
you are given to be used topically during the trial will be the herbal cream or a 
cream that looks identical to the herbal cream but is inactive.  You are 
welcome to examine the test cream sample before deciding whether you want 
to participate the trial.  You will have to apply the cream two times a day for 8 
weeks and will not know whether you have received herbal cream or dummy 
cream until the trial is completed.  However, the identity of the cream can be 
determined immediately if any adverse reaction develops. 
 
You will not be allowed to use any steroid drugs orally during the trial period.  
If you have to use steroid topically during the trial period, you should record 
and report the drug that you use. You can continue to use emollients to 
moisten the dry skin if you have done so before enrolling this trial.  There is 
no need to change your life style or diet during the trial period. 
 
 
5. Risk 
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If you are unduly concerned about your responses to any of the questionnaire 
items or if you find participation in the project distressing, you should contact 
Sherman Gu as soon as convenient. Mr. Gu will discuss your concerns with 
you confidentially and suggest appropriate follow-up, if necessary. The herbal 
formula has been used clinically both in China and Australia for years and 
there is no evidence to show adverse reaction in relation to the application of 
the preparation.  If there is any serious adverse reaction occurs, you should 
stop using the Chinese herbal cream immediately and you will be treated 
promptly.   
 
 
6. Benefits 
The Chinese herbal cream has been shown its effectiveness in treatment of 
atopic eczema; therefore, your condition might be improved once the full 
course of treatment completed.  Of course, this is not guaranteed or promised 
and you might not receive the Chinese herbal cream treatment.  However, if 
you are not in the treatment group, then you will be given the same herbal 
cream to treat the same condition if the herbal cream has demonstrated its 
effectiveness and safety with 3 months after the trial is completed. 
 
 
7. Confidentiality of the Records 
Information you provide in this trial will be maintained in confidentiality.  No 
identity of any participant in this trial will be disclosed in any public reports or 
publications.  However, for purpose of monitoring, supervision and review of 
the trial, identified data will be seen by a small number of people such as the 
project supervisors, consultants and personnel from RMIT Human Research 
Ethic Committee.  Any information that you provide can be disclosed only if 
(1) it is to protect you or others from harm; (2) a court order is produced; or 
(3) you provide the researchers with written permission. Storage and 
disclosure of the information in this trial will be strictly under the guidance of 
the Australian Government Joint NHMRC / AVCC Statement and Guidelines 
on Research Practice 1997.   The research data will be kept securely at RMIT 
for a period of 15 years before being destroyed.  
 
8. If Problem Develops 
If any serious adverse event or reaction develops, you will receive prompt and 
appropriate Chinese medicine (CM) attention.  It is agreed that the RMIT 
Complementary Medicine Teaching Clinic will be made available to you.  
Reasonable CM treatment will be free when provided through the RMIT 
Complementary Medicine Teaching Clinic.  RMIT has in place public and 
products liability insurance covering legal liability of the insured to pay 
damages or compensation in respect of personal injury or damage to property 
as a result of an occurrence happening in connection with the proposed clinical 
trial. 
 
9. Financial Considerations 
There will be no financial benefits to you or your family for participating in 
this trial. 
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10. Obtaining Additional Information 
You can ask any questions that occur to you at this time or at any time during 
your participation in the trial.  You will be given a copy of this agreement for 
your own information.  You can also contact Mr. Gu on 0419 396 963. 
 
11. Rights as a Participant 
You are free to withdraw your consent to participate in this trial at any time 
without prejudice.  If you select to do so, your right to present or future CM 
care by Mr. Gu or at RMIT Complementary Medicine Teaching Clinic will not 
be affected.  You have the right to have any unprocessed data withdrawn and 
destroyed, provided it can be reliably identified, and provided that so doing 
does not increase the risk for the participant.  You also have the right to have 
any questions answered at any time. 
 
Yours sincerely, 
 
Sherman Gu BMed 
Signature: ________________________ 
 
Chun Guang Li PhD 
Signature: ________________________  
 
Angela Wei Hong Yang PhD 
Signature: ________________________  
 
Charlie Xue PhD 
Signature: ________________________  
Any complaints about your participation in this project may be directed to the Executive 
Officer, RMIT Human Research Ethics Committee, Research & Innovation, RMIT, GPO Box 
2476V, Melbourne, 3001.  
Details of the complaints procedure are available on the ‘Complaints with respect to 
participation in research at RMIT’ page 
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Appendix 9 Prescribed Consent Form for Persons 
Participating in Research Projects Involving 
Interviews, Questionnaires or Disclosure of 
Personal Information 
 
 
College  Science, Engineering and Health 
School of Health Sciences 
Name of participant:  
Project Title: Pilot Randomised Control Trial of Topical Application of 
Chinese Herbal Medicine Cream for Atopic Eczema 
Name(s) of investigators:        (1)    Sherman Gu Phone: (03) 9800 3969 
(2) Chun Guang Li Phone: (03) 9925 7635 
(3) Angela Wei Hong Yang Phone: (03) 9925 7175 
(4) Charlie Xue Phone: (03) 9925 7745 
 
1. I have received a statement explaining the interview/questionnaire involved in 
this project. 
 
2. I consent to participate in the above project, the particulars of which - 
including details of the interviews or questionnaires - have been explained to 
me. 
 
3. I authorise the investigator or his or her assistant to interview me or administer 
a questionnaire. 
 
4. I acknowledge that: 
 
(a) Having read Plain Language Statement, I agree to the general purpose, 
methods and demands of the study. 
(b) I have been informed that I am free to withdraw from the project at any 
time and to withdraw any unprocessed data previously supplied. 
(c) The project is for the purpose of research and/or teaching. It may not be 
of direct benefit to me. 
(d) The privacy of the personal information I provide will be safeguarded 
and only disclosed where I have consented to the disclosure or as 
required by law.   
(e) The security of the research data is assured during and after completion 
of the study.  The data collected during the study may be published, and 
a report of the project outcomes will be provided to____________ 
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(researcher to specify).   Any information which will identify me will not 
be used. 
 
Participant’s Consent 
 
 
Participant:  Date :  
(Signature) 
 
 
Witness:  Date:  
(Signature) 
 
Where participant is under 18 years of age: 
 
I consent to the participation of ____________________________________ in the 
above project. 
 
Signature: (1)                                             (2) Date:  
(Signatures of parents or guardians) 
 
Witness:  Date:  
(Witness to signature) 
 
Participants should be given a photocopy of this consent form after it has been signed. 
 
Any complaints about your participation in this project may be directed to the Executive 
Officer, RMIT Human Research Ethics Committee, Research & Innovation, RMIT, GPO Box 
2476V, Melbourne, 3001.  
Details of the complaints procedure are available on the ‘Complaints with respect to 
participation in research at RMIT’ page 
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Appendix 10 Prescribed Consent Form for Persons 
Participating in Research Projects Involving 
Tests and/or Medical Procedures 
 
 
 
College  Science, Engineering and Health 
School of Health Sciences 
Name of participant:  
Project Title: Pilot Randomised Control Trial of Topical Application of 
Chinese Herbal Medicine Cream for Atopic Eczema 
Name(s) of investigators:        (1)    Sherman Gu Phone: (03) 9800 3969 
(2) Chun Guang Li Phone: (03) 9925 7635 
(3) Angela Wei Hong Yang Phone: (03) 9925 7175 
(4) Charlie Xue Phone: (03) 9925 7745 
 
 
1. I have received a statement explaining the tests/procedures involved in this 
project. 
 
2. I consent to participate in the above project, the particulars of which - 
including details of tests or procedures - have been explained to me. 
 
3. I authorise the investigator or his or her assistant to use with me the tests or 
procedures referred to in 1 above. 
 
4. I acknowledge that: 
 
(a) The possible effects of the tests or procedures have been explained to me 
to my satisfaction. 
(b) I have been informed that I am free to withdraw from the project at any 
time and to withdraw any unprocessed data previously supplied (unless 
follow-up is needed for safety). 
(c) The project is for the purpose of research and/or teaching.  It may not be 
of direct benefit to me. 
(d) The privacy of the personal information I provide will be safeguarded 
and only disclosed where I have consented to the disclosure or as 
required by law.  
(e) The security of the research data is assured during and after completion 
of the study.  The data collected during the study may be published, and 
a report of the project outcomes will be provided to________ (researcher 
to specify).   Any information which will identify me will not be used. 
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Participant’s Consent 
 
Participant:  Date:  
(Signature) 
 
 
Witness:  Date:  
(Signature) 
 
Where participant is under 18 years of age: 
 
I consent to the participation of ____________________________________ in the 
above project. 
 
Signature: (1)                                             (2) Date:  
(Signatures of parents or guardians) 
 
Witness:  Date:  
(Witness to signature) 
 
Participants should be given a photocopy of this consent form after it has been signed. 
 
 
Any complaints about your participation in this project may be directed to the Executive 
Officer, RMIT Human Research Ethics Committee, Research & Innovation, RMIT, GPO Box 
2476V, Melbourne, 3001.  
Details of the complaints procedure are available on the ‘Complaints with respect to 
participation in research at RMIT’ page 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 11  General Information Questionnaires 
 
(All Information provided will be strictly confidential abiding to States and Commonwealth 
statues. Please fill in the form carefully and thoroughly.) 
 
 
Title: _______ Family Name: __________________________ Given Name: _______________________ 
Date of Birth: _____________ Occupation: ____________________________  Gender:   Female  Male 
Address: ________________________________________________________ Postcode: ____________ 
Phone: ___________________(Home) ____________________(Work) ____________________(Mobile) 
Email address: ______________________________________________________________________ 
Do you have any known Allergies?  No  Yes ______________________________(Please indicate) 
Please list previous illness, accidents and surgeries: _______________________________________ 
__________________________________________________________________________________  
Do you or any of your family members have atopic eczema, asthma or allergic rhinitis?  
__________________________________________________________________________________ 
Please list your current medical conditions and medications: ____________________________ 
 
 
Your Medicare Number: ________________  Your family doctor: ___________________________  
 
How do you come to know this trial?  
 Family or Friends    Media    Internet    Others ____________________(Please indicate) 
 
 
Signature: ______________________________(Guardian if applicable) Date: ___________________ 
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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 Appendix 12  Inclusion/Exclusion Criteria 
   (Screening Instruments) 
Instructions: 
This form should be completed by a trial investigator with consultation of the 
participant or his/her guardian on the screening stage of the trial.  An eligible participant 
must be in keep with Criterion 1 plus at least 3 out of Criteria 2 to 6 and all of Criteria 
7, 8 and 9 of the Inclusion criteria. 
 
 Inclusion Criteria 
 Questions Yes No 
1 Do you have a history of skin itchiness in the last 12 months   
2 Do you have history of flexural involvement    
3 Do you have flexural dermatitis    
4 Did the skin condition start under 2 years old (not used for children 
under 4 years old)  
  
5 Are you 12 months or 12 months above   
6 Do you have history of atopic disorders, such as asthma, allergic 
rhinitis or hay fever 
  
7 First baseline objective SCORAD score ≥ 15   
8 Second baseline objective SCORAD score ≥ 15 (in an interval of 2 
weeks) 
  
9 Have you signed the informed consent form and expressed your 
compliance with the requirements of the trial 
  
Exclusion Criteria 
1 Have you been using corticosteroids orally in the past 30 days    
2 Have you been using any preparation of Chinese herbal medicines or 
other herbs for treatment of the skin eczematous changes orally in 
the past 30 days 
  
3 Have you been diagnosed by dermatologist with scabies for your 
present skin condition 
  
4 Have you been diagnosed by dermatologist with allergic contact 
dermatitis for your present skin condition 
  
5 Have you been diagnosed by dermatologist with seborrheic 
dermatitis or psoriasis for your present skin condition 
  
6 Have you been diagnosed by dermatologist with psoriasis for your 
present skin condition 
  
7 Are you less than 12 months old   
8 Are you currently pregnant   
9 Do you have any history of  renal dysfunction   
10 Do you have any history of  liver dysfunction   
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 13 Record Sheet of Withdrawals/Dropouts of the 
Participants  
 
 
Participant’s 
ID 
Date of 
Withdrawal/ 
Dropout 
Reason(s) of 
Withdrawal/ 
Dropout 
Proper 
Unprocessed Data 
Withdrawn and 
Destroyed 
Signature of the 
Investigator 
     
     
     
     
     
     
     
     
     
     
     
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 14 Chinese Medicine Syndrome Identification for 
AE∗ 
 
 
Instructions: 
This form should be completed by a trial investigator with consultation of the 
participant or his/her guardian on the screening stage of the trial.  Please tick þ one 
column for relevant symptom(s) or sign(s). 
 
 
Syndrome Main Symptoms and Signs Associate Symptoms and Signs 
Blood 
Deficiency 
with wind 
& Dryness 
Dryness 
and 
thickening 
of the skin 
Itchiness 
with 
excoriation 
and blood 
crusts 
Abdominal 
bloating 
after eating 
Constipations 
or loose 
stools 
Pale and 
flabby 
tongue 
body 
White 
tongue 
coating 
Slippery 
pulse 
       
 
Retention 
of wind & 
dampness 
on the skin 
Redness 
on the skin 
Severe 
itchiness 
Scratches 
with 
erosion 
and ooze 
Low 
energy 
Loose 
stools 
Pale 
tongue 
body 
Thin, 
greasy 
tongue 
coating 
Wiry 
and 
slippery 
pulse 
         
 
 
 
 
Registered Chinese medicine practitioner’s signature: ____________________ 
 
                                                 
∗
 This form was modified and translated from “Criteria of Diagnosis and Therapeutic Effect of Diseases 
and Syndromes in TCM (ZY/T001.8-94)” published by the State Administration of TCM, P. R. of China, 
1994   
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 15 Instructions for Completing Case Report 
Forms 
 
• Pen:     
 
Always use a black ball-point pen when writing in case report forms. 
 
• Text:    
 
Please write clearly in legible English. 
 
• Identification of participant:  
 
Please ensure that the participant number & initials are clearly stated on the 
designated portion of each page. 
 
• Missing/unavailable data:  
 
Please do not leave data boxes empty. If data is missing, put a single line through 
the blank section and add a comment stating why the data was not available eg “not 
done”   
 
• Abnormal data:  
 
Please give the reason for any abnormal data in the space provided in the CRF. 
 
• Corrections:  
 
Please do not make changes with correction fluid. Draw a single line through the 
incorrect value so that it is still legible.  Write the correct value clearly as near as 
possible to the original value.  Initial and date the change. 
 
• Dates:  
 
Please write dates using this order: day, month, and year. 
 
• Times:  
 
Please document times using 24-hour notation. 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 16 Assessment Form for Objective Score of 
SCORAD∗  
 
 
Instructions: 
This form should be completed by a trial investigator with consultation of the 
participant or his/her guardian on the stages of screening, treatment, endpoint and 
following up at a minimum interval of 2 weeks. 
 
A. Extent      Please tick the area involved and write down the sum score  
 
1. Table for children under two years 
 
1a. the front 
 
 Anterior 
head 
Left 
anterior 
arm 
Right 
anterior 
arm 
Anterior 
torso 
Left 
anterior 
leg 
Right 
anterior 
leg 
Left 
palm 
Right 
palm 
Genital/perineum 
Score 8.5 4.5 4.5 18 6 6 1 1 1 
Sum          
 
1b. the back 
 
 Posterior 
head 
Left 
posterior 
arm 
Right 
posterior 
arm 
Posterior 
torso 
Left 
posterior 
leg 
Right 
posterior 
leg 
Left 
hand 
Right 
hand 
Score 8.5 4.5 4.5 18 6 6 1 1 
Sum         
 
2. Table for adults 
 
2b. the front 
 
 Anterior 
head 
Left 
anterior 
arm 
Right 
anterior 
arm 
Anterior 
torso 
Left 
anterior 
leg 
Right 
anterior 
leg 
Genital/perineum 
Score 4.5 4.5 4.5 18 9 9 1 
Sum        
 
                                                 
∗
 This form was adapted and modified from Stalder, J. F., & Taieb, A. (1993).  Severity scoring of atopic 
dermatitis: The SCORAD Index Consensus Report of the European Task Force on Atopic Dermatitis. 
Dermatology (186), 23-31.   
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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2b. the back 
 
 Posterior 
head 
Left 
posterior 
arm 
Right 
posterior 
arm 
Posterior 
torso 
Left 
posterior 
leg 
Right 
posterior leg 
Score 4.5 4.5 4.5 18 9 9 
Sum       
 
 
 
B. Intensity Please write down the sum score  
 
 
Criteria 0 absence 1 mild 2 moderate 3 severe 
Erythema/darkening     
Edema/papulation     
Oozing/crust     
Excoriation     
Lichenification/prurigo     
Dryness (is evaluated 
on uninvolved areas 
    
 
 
Objective SCORAD: 
 
A/5 + 7B/2 =              /83
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 17 Visual Analogue Scale for Assessment of 
Severity of AE (Subjective SCORAD) ∗ 
 
 
Instructions: 
Point 1 and 2 on this form should be completed by patient or guardian with 
assistance of a trial investigator.  Point 3 should be a sum of scores on Point 1 and Point 
2 and filled in by a trial investigator. 
 
 
 
1. Please circle the number on the table to scale your average for the last 3 days or 
night in term of skin itch, 0 is no skin itch at all; 5 is moderate and 10 is very poor. 
 
0 1 2 3 4 5 6 7 8 9 10 
 
Pruritus (itch) (0 to 10) 
 
 
2. Please circle the number on the table to scale your average for the last 3 days or 
night in term of sleep loss, 0 is no sleep loss at all; 5 is moderate and 10 is very poor. 
 
0 1 2 3 4 5 6 7 8 9 10 
 
Sleep Loss (0 to 10) 
 
 
3. Subjective SCORAD (Pruritus + Sleep loss) score:  
 
                                                 
∗
 This form was adapted and modified from Stalder, J. F., & Taieb, A. (1993). Severity scoring of atopic 
dermatitis: The SCORAD Index Consensus Report of the European Task Force on Atopic Dermatitis. 
Dermatology (186), 23-31.   
 
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 18 Infant’s Dermatitis Quality of Life Index 
(IDQOL) ∗ 
 
1. Instructions: 
  The aim of this table is to record how your child’s dermatitis has been.  Each 
question concerns THE LAST WEEK ONLY.  Please answer and circle every question.  
The form is designed for a participant under 4 years old. 
 
 
 
 Questions 
1 Over the last week, how much has your child 
been itching and scratching?  
All the 
time 
A lot A little None 
2 Over the last week, what has your child’s mood 
been? 
Always 
crying, 
extremely 
difficult 
Very 
fretful 
Slightly 
fretful 
Happy  
3 Over the last week approximately how much 
time to get your child off to sleep each night? 
More 
than 2 
hrs 
1 - 2 
hrs 
15mins 
- 1 hr 
0-
15mins 
4 Over the last week, what was the total time that 
your child’s sleep was disturbed on average 
each night? 
5 hrs or 
more 
3 - 4 
hrs 
1 - 2 
hrs 
Less 
than 1 
hour 
5 Over the last week, has your child’s eczema 
interfered with playing or swimming? 
Very 
much 
A lot A  little Not at 
all/None 
6 Over the last week, has your child’s eczema 
interfered with your child taking part in or 
enjoying other family activities? 
Very 
much 
A lot A  little Not at 
all/None 
7 Over the last week, have there been problems 
with your child at mealtimes because of the 
eczema? 
Very 
much 
A lot A  little Not at 
all/None 
8 Over the last week, have there been problems 
with your child caused by the treatment? 
Very 
much 
A lot A  little Not at 
all/None 
9 Over the last week, has your child’s eczema 
meant that dressing and undressing the child 
has been uncomfortable? 
Very 
much 
A lot A  little Not at 
all/None 
10 Over the last week how much has your child 
having eczema been a problem at bathtime? 
Very 
much 
A lot A  little Not at 
all/None 
 
                                                 
∗
 IDQOL was adapted and modified from Lewis-Jones, M. S., Finlay, A. Y., & Dykes, P. J. (2001). The 
infants' dermatitis quality of life index. British Journal of Dermatology (144), 104-110 with permission of 
the authors for research purpose. 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Please check that you have answered EVERY question. Thank you.  
 
IDQOL score:  
 
2. Scoring: 
 
Questions 1 and 5-10 
 
All the time scored 3 
A lot scored 2 
A little scored 1 
None scored 0 
 
Question 2 
Always crying etc. scored 3 
Very fretful  scored 2 
Slightly fretful scored 1 
Happy scored 0 
 
Question 3 
More than 2 hrs scored 3 
1-2 hrs scored 2 
15 mins-1hr scored 1 
0-15 mins scored 0 
 
Question 4 
5hrs or more scored 3 
3-4 hours scored 2 
1-2 hours scored 1 
Less than 1 hour scored 0 
 
Question 5-10 
Very much scored 3 
A lot scored 2 
A little scored 1 
Not at all / none scored 0 
 
The IDQOL is calculated by summing the score of each question resulting in a 
maximum of 30 and a minimum of 0. The higher the score the more quality of life is 
impaired.  
 
(Please Note: That the scores associated with the different answers on Point 2 
Scoring should not be printed on the IDQOL itself, as this might cause bias). 
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 19 Children's Dermatology Life Quality Index 
(CDLQI)∗ 
 
1. Instructions: 
The aim of this questionnaire is to measure how much your skin problem has 
affected you OVER THE LAST WEEK.  Please tick þ one column for each question. 
The form is designed for a participant at age of 5 to 16.  
 
 
 Questions Very 
much 
Quite 
a lot 
Only a 
little 
Not at 
all 
1 Over the last week, how itchy, "scratchy", sore or painful 
has your skin been?  
    
2 Over the last week, how embarrassed or self conscious, 
upset or sad have you been because of your skin? 
    
3 Over the last week, how much has your skin affected your 
friendships? 
    
4 Over the last week, how much have you changed or worn 
different or special clothes/shoes because of your skin? 
    
5 Over the last week, how much has your skin trouble 
affected going out, playing, or doing hobbies? 
    
6 Over the last week, how much have you avoided swimming 
or other sports because of your skin trouble? 
    
7a If school time: Over the last week, how much did your skin 
problem affect your school work?   
                                                        Prevented school     r  
    
7b If holiday time: How much over the last week, has your 
skin problem interfered with your enjoyment of the 
holiday? 
    
8 Over the last week, how much trouble have you had 
because of your skin with other people calling you names, 
teasing, bullying, asking questions or avoiding you? 
    
9 Over the last week, how much has your sleep been affected 
by your skin problem? 
    
10 Over the last week, how much of a problem has the 
treatment for your skin been? 
    
 
Please check that you have answered EVERY question. Thank you.  
 
CDLQI score:  
                                                 
∗
 CDLQI was adapted and modified from Lewis-Jones, M. S., & Finlay, A. Y. (1995). The children's 
dermatology life quality index (CDLQI): initial validation and practical use. British Journal of 
Dermatology, 132(6), 942-949 with permission of the authors for research purpose. 
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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2. Scoring: 
 
The scoring of each question is as follows:  
 
Very much scored 3 
Quite a lot scored 2 
Only a little scored 1 
Not at all scored 0 
Question unanswered scored 0 
Question 7: "Prevented school" scored 3 
 
The CDLQI is calculated by summing the score of each question resulting in a 
maximum of 30 and a minimum of 0. The higher the score, the more quality of life is 
impaired. The CDLQI can also be expressed as a percentage of the maximum possible 
score of 30.  
 
(Please Note: That the scores associated with the different answers on Point 2 
Scoring should not be printed on the CDLQI itself, as this might cause bias). 
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 20 Dermatology Life Quality Index (DLQI) ∗ 
 
1. Instructions: 
The aim of this questionnaire is to measure how much your skin problem has 
affected you OVER THE LAST WEEK.  Please tick þ one column for each question.  
The form is designed for a participant at age of 17 or more.  
 
 
 Questions Very 
much 
A lot A little Not at 
all 
1 Over the last week, how itchy, sore, painful or 
stinging has your skin been?  
    
2 Over the last week, how embarrassed or self 
conscious, have you been because of your skin? 
    
3 Over the last week, how much has your skin 
interfered with you going shopping or looking after 
your home or garden? 
   
or Not 
relevant 
4 Over the last week, how much has your skin 
influenced the clothes you wear? 
   
or Not 
relevant 
5 Over the last week, how much has your skin affected 
any social or leisure activities?  
   
or Not 
relevant 
6 Over the last week, how much have your skin made it 
difficult for you to do any sport? 
   
or Not 
relevant 
7a Over the last week, has your skin prevented you from 
working or studying?    Yes  r         No r  
Do 
not 
fill 
here 
Do 
not 
fill 
here 
Do not 
fill 
here 
or Not 
relevant 
7b If "No", over the last week how much has your skin 
been a problem at work or studying? 
Do 
not 
fill 
here 
  
Not at 
all 
8 Over the last week, how much has your skin created 
problems with your partner or any of your close 
friends or relatives? 
   
or Not 
relevant 
9 Over the last week, how much has your skin caused 
any sexual difficulties?  
   
or Not 
relevant 
10 Over the last week, how much of a problem has the 
treatment for your skin been, for example by making 
your home messy, or by taking up time? 
   
or Not 
relevant 
                                                 
∗
 DLQI was adapted and modified from Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality 
index (DLQI)--a simple practical measure for routine clinical use. Clinical & Experimental Dermatology 
19(3), 210-216 with permission of the authors for research purpose. 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Please check that you have answered EVERY question. Thank you.  
 
DLQI score:  
 
 
2. Scoring: 
 
The scoring of each question is as follows:  
 
Very much scored 3 
A lot scored 2 
A little scored 1 
Not at all scored 0 
Not relevant scored 0 
Question unanswered scored 0 
Question 7: "prevented work or studying" scored 3 
 
 
The DLQI is calculated by summing the score of each question resulting in a 
maximum of 30 and a minimum of 0. The higher the score, the more quality of life is 
impaired. The DLQI can also be expressed as a percentage of the maximum possible 
score of 30.  
 
(Please Note: That the scores associated with the different answers on Point 2 
Scoring should not be printed on the DLQI itself, as this might cause bias). 
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 21 Daily Medical Record Sheet 
 
This daily sheet should be recorded by the patient or his/her guardian every day 
when you are on the period of the trial.  Please take the record sheet for evaluation next 
time when you re-visit the trial center. 
 
Please circle the number on the table to scale the average of the itching and sleep 
loss.  0 is not at all; 5 is moderate and 10 is very severe. 
 
0 1 2 3 4 5 6 7 8 9 10 
Itching of the skin (0 – 10) 
 
0 1 2 3 4 5 6 7 8 9 10 
Sleep loss (0 – 10) 
 
Please circle the number on the table to scale the average intensity of the signs on your 
skin.  
 
0 absence 1 mild 2 moderate 3 severe 
Redness of the skin 
 
0 absence 1 mild 2 moderate 3 severe 
Dryness of the skin 
 
0 absence 1 mild 2 moderate 3 severe 
Thickness of the skin 
 
 
If any adverse reaction develops, please fill in the form “Adverse Event 
Questionnaires” separately. 
 
Date 
& 
Time 
Usage of 
the 
Chinese 
Herbal 
Cream 
Itching  
of The 
Skin 
(0 To 10) 
Sleep 
Loss 
(0 To 10) 
Redness 
of the 
Skin 
(0 To 10) 
Dryness 
of the 
Skin 
(0 To 10) 
Thick-
Ness of 
the Skin 
(0 To 10) 
Application 
of other 
Medicines 
(Dosage & 
Name of the 
Medication) 
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Please add additional sheet if there is not enough space. 
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Appendix 22  Outcome Measures Sheet 
 
Instruction:  This form is designed for out measures assessed and recorded by the trial 
investigator. 
 
Participant’s 
ID 
Date of 
Measurement 
Subjective Sore 
of SCORAD 
(Self Rated 
Symptoms and 
Signs) 
Objective 
Score of 
SCORAD 
Score 
of QoL 
Blood 
Tests 
Results 
Adverse 
Reaction 
Baseline 
Day 1-14 
     
Day 15      
Day 29      
Day 43      
Day 57      
Endpoint 
Day 71 
     
 
Day 99 
Follow- up 
     
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
 132 
 
 
RMIT 
UNIVERSITY 
 
Traditional & Complementary Medicine Research Group, School of Health Sciences 
 
 
Appendix 23 Pathology Tests 
 
Participant’s Last Name:  Given Name:  Sex: Date of Birth: 
 
 
Participant’s Address:  
 
 
Tel: (H)   Tel: (B)   Your Ref: 
 
Medicare Card Number: 
 
 
 
Tests Requested: 
 
Full blood tests Liver function tests  Renal function tests  IgE 
 
Pregnancy test (only if applicable) 
 
 
 
 
 
 
Clinical notes: 
 
 
 
Copy reports to: 
 
 
 
Requesting doctor (Provider number, initials, surname, and address): 
 
 
 
 
 
 
Doctor’s signature and request date: 
 
Participant’s Initials:                                    Participant’s ID:                        Date: ___/___/_____ 
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Appendix 24 Adverse Event Questionnaires 
 
Please record any unexpected feelings or symptoms or signs during participation 
of the trial on the following table and report any severe adverse event to the investigator 
on (03) 9925 7635 and stop using the intervention products immediately until further 
instruction is given. 
Please scale the severity of the event by using the VAS table below and write 
down the score on the Record Sheet of Adverse Event.  0 is not at all, 5 is moderate and 
10 is very severe.  
 
 
1. VAS table 
 
 
0 1 2 3 4 5 6 7 8 9 10 
 
2. Record Sheet of Adverse Event 
 
Type of Event 
(symptoms 
and/or signs) 
When was that 
happen? (date and 
time) 
How long did it 
last for? 
Severity of the 
event (0 to 10) 
What action did 
you do for the 
event? 
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Appendix 25 Record Sheet of the Compliance Check 
 
 
Participant’s 
ID 
Visit Date & Day Sequential 
Number of the 
Container 
Weight of 
Returned 
Creams 
Investigator’s 
Signature 
 Day 29    
 Day 43    
 Day 57    
 Day 71    
 Day 99 
Follow-up 
   
 
 
 
 
